<< Back to podcast list Strategic Partner(s) Dr. Alix A. J. Rouault About Dr. Alix A. J. Rouault "My contribution to science began during the equivalent of U.S. masters training at the Université de Bretagne Occidentale (UBO; France). Under the leadership of Dr. Karine Pichavant , I contributed to the development of a drug to treat hypovolemic shock after severe hemorrhage. During this time, Dr. Olivier Mignen , the director of another research unit at the UBO recommended me to Dr. Julien Sebag , a researcher at the University of Iowa. I spent two years working with Dr. Sebag as an exchanged scholar while my student visa was in the work, during which time I thoroughly reviewed the literature on the melanocortin receptor accessory protein 2 (MRAP2), resulting in my first peer-reviewed publication in Biochimica et Biophysica Acta (BBA). I then undertook my first project where I demonstrated that MRAP2 regulates the signaling of multiple G protein-coupled receptors (GPCRs) through different structural regions. This project yielded my first, first author publication in BBA – Molecular Cell Research, and a book chapter for Neuromethods on a technique I adapted to measure the mitochondrial pyruvate oxidation in primary neurons. In 2017 I officially joined the PhD program in the Department of Molecular Physiology and Biophysics at the University of Iowa Carver College of Medicine, under the mentorship of Dr. Sebag. During my PhD, I continued my studies on MRAP2. I contributed to an In-vivo project that showed that MRAP2 regulates the growth hormone secretagogue receptor-1a (GHSR1a), the results of which are published in Nature Communications. Concurrently, I described the mechanisms by which MRAP2 regulates GHSR1a signaling; this project brought forth our NanoBiT-based arrestin recruitment assay. At the time, NanoBiT was a prototype technology we gained access to by collaborating with Promega. This powerful tool allowed us to create an assay that kinetically measured the arrestin recruitment to an activated GPCR for the first time. Using this novel technique, I showed that MRAP2 biased GHSR1a signaling and shut down its constitutive activity; this work resulted in a first author publication in Science Signaling. While writing my thesis, I published another paper in the Journal of Biological Chemistry which described the molecular mechanisms of MRAP2 regulation of the GHSR1a, and where I notably developed the C-terminal gate theory. This theory states that the post-translational modification of GHSR1a’ C-terminal tail is not a docking space for the arrestins, but rather a necessary modification leading to a structural change granting the arrestins access to the core of the receptor. Some of my data were also used in an In-vivo study published in iScience, showing the relevance of the MRAP2 regulatory effect on GHSR1a in pancreatic islets. Dr. Cone’s lab was a clear choice for a postdoc. Dr. Cone was the first to clone the melanocortin receptors (the GPCRs that led to the discovery of MRAP2), and his lab works is highly In-vivo oriented. Since I joined the lab, I became proficient in many In-vivo techniques, I adapted my arrestin recruitment assay to a high throughput screening format for drug discovery, I have started molecular work on the melanocortin receptors. I also invested a tremendous amount of time in developing my leadership skills. I spent time running for the chair of International Affairs for the U-M Postdoctoral Association (UMPDA). Further, I applied to create a scientific session at the American Physiology Summit (APS) 2024 dedicated to GPCR biased signaling. Dr. Lauren Slosky and Dr. Joshua Gross were enthusiastic about the idea and jumped on board. Our session was picked up by the APS. We were pleasantly surprised by the interest generated by our scientific session, Dr. Michel Bouvier accepted to open our session and will be followed by Dr. John McCorvy , Dr. Dylan Eiger , and Joshua Gross. We are very excited about this event. At this point in my career, I am creating connections with biomedical industry, assessing professional opportunities, and seriously weighing strengths of career options across sectors; however, academia does not make information about industry widely accessible to trainees. This is, in part, why I ran for, and was elected Chair of International Affairs of the University of Michigan Postdoc Association. I want to connect more trainees with diverse career resources to support professional decision-making. I am hopeful that my efforts to support the professional opportunities of my peers, in combination with my own scientific endeavors, will inform my future career decisions." Dr. Alix A. J. Rouault on the web University of Michigan Carver College of Medicine ResearchGate Google Scholar Dr. GPCR Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Career coach Lauren Solano on the skills PhDs undersell, the careers they don't know exist, and the introspection exercise that maps functions to scientific training. << Back to podcast list Strategic Partner(s) Lauren Solano: Mapping Careers Beyond the Bench This episode steps outside the usual GPCR research conversation to examine the career architecture around it. Lauren Solano, CEO and co-founder of Propel Careers, has spent more than a decade coaching PhDs and postdocs and recruiting for biotech and life sciences companies — a vantage point that makes her uncommonly clear about the gap between how scientists describe themselves and how the market reads them. The discussion explores how to translate scientific training into career options that are often invisible to bench scientists, ranging from medical science liaison and clinical research roles to business development, scientific communications, venture capital, and consulting. Solano unpacks the specific transferable skills PhDs consistently undersell — collaboration, leadership, proactive ownership, communicating across technical audiences — and introduces concrete tools for self-assessment and exploration, including the "loved it, loathed it" exercise and a permission-granted approach to informational interviewing. For Solano, the stakes are personal: she didn't know the career she now has was even possible in 2008, which is precisely why she maps the option space for the scientists she coaches today. About the Guest Lauren Solano is CEO and co-founder of Propel Careers, a Boston-based firm that coaches scientists and recruits for biotech and life sciences companies. She trained as a scientist and spent her first decade in preclinical and early clinical drug discovery before pursuing an MBA in 2007 and co-founding Propel in 2009. Her practice centers on helping PhDs and postdocs translate technical training into career paths they often don't realize are open to them. Each year she delivers roughly a hundred talks at universities and research institutions on resumes, negotiation, informational interviewing, and the mechanics of biotech hiring. Scientific Themes of the Conversation The gap between scientific training and the career vocabulary scientists need Transferable skills in the PhD toolkit — and why they go unlisted Informational interviewing as a research method for career planning The limits and real signals of "company culture" in biotech COVID-era shifts in scientist hiring and career reflection Title-function mismatches in life sciences job descriptions Key Insights from the Conversation 1. The "loved it, loathed it" exercise as a career compass Over any given week, note which tasks you enjoyed and which you dreaded. Separate that list from what you're good at — the overlap reveals which career functions, not titles, are worth exploring next. 2. Function over title Job titles in biotech are often creative and inconsistent — a medical science liaison might be called a "clinical information specialist." Scientists navigating a career change are better served mapping careers by tasks and functions first, and treating titles as secondary metadata. 3. PhDs consistently undersell their transferable skills After thousands of conversations with scientists, Solano has found that collaboration, leadership, proactive ownership, and translating technical content across audiences are not universal traits. PhDs tend to have them in unusual concentration — and tend to leave them off their resumes because they assume everyone else has them too. 4. Informational interviews are already permitted Graduate students and postdocs often feel uneasy reaching out to people in other careers, as if the exploration hasn't been earned. Solano reframes this directly: because training ends, career exploration is required, and most people will give fifteen minutes if asked well. 5. "Company culture" is meaningless until you can point at behaviors Every company claims a strong culture. What matters is whether office layout, mentorship practices, and daily behaviors support the claim. The sharper question is what the company does , not what it says. 6. Safety at work is a concrete culture signal Would an employee feel comfortable telling a manager their child is sick, or would they invent another reason? Whether people feel safe at work is a harder measure of culture than any mission statement. 7. Post-pandemic career decisions are about alignment, not just advancement Solano observes that many scientists are using the moment to ask whether their current work matches who they are — not to chase the next rung, but to reset toward impact. Episode Timeline 00:00 Intro and Dr. GPCR Summit preview 01:30 Meet Lauren Solano and Propel Careers 03:11 The path from bench science to career coaching 07:56 Loved it, loathed it — the introspection exercise 10:29 Career options PhDs rarely consider 11:49 Transferable skills scientists undervalue 14:16 The informational interview — permission granted 23:57 The COVID shift in biotech hiring 26:14 Assessing real company culture 31:34 Master resumes and the title trap Timestamps were generated using AI for readability. Selected Quotes "If you had asked me in 2008 if I would be a recruiter slash career coach, I didn't even know that was possible because it hadn't even occurred to me that that is something that would have been a fit." "None of you should be ever worried or afraid or feel awkward reaching out to people for informational interviews because you are supposed to think about your future and learn about different things." "I can tell you in speaking with thousands of PhDs, not everyone is collaborative. Not everyone likes to do novel areas of research. Not everyone is amazing at communicating both to technical audiences and non-technical audiences. So don't undersell your experiences." "Life is frail, right? So if we're not making a difference, if we're not impacting something, why are we doing it?" About this episode In this special Dr. GPCR podcast episode, we sat down to chat with Lauren Celano to talk about career options for Ph.D.’s. Working in a lab allows scientists to gain amazing hard and soft skills, which opens the doors to several great careers that many have not even considered, yet. Lauren has a science background and is passionate about helping talented scientists find their dream position. She is also a speaker, connector, recruiter, and coach. Lauren Celano on the web LinkedIn Propel Careers Email: Lauren@propelcareers.com Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. John Janetzko About Dr. John Janetzko "I received my Honors BSc in Chemistry from the University of Toronto in 2011, with a focus on synthetic organic and inorganic chemistry. Following this, I pursued graduate studies in Chemistry at Harvard University. At Harvard, I worked in the labs of Drs. Daniel Kahne and Suzanne Walker studying the structure and function of the essential human enzyme, O-GlcNAc transferase (OGT). My Ph.D. work focused on understanding the mechanism of an enigmatic moonlighting function of OGT that had been described only a year earlier. Over the course of my graduate work, I gained experience with structural mass spectrometry and protein crystallography, which shaped my interest in understanding how protein dynamics are linked to function. To further develop these ideas, I joined the lab of Dr. Brian Kobilka at Stanford University at the end of 2017 for postdoctoral work. There, I’ve been working towards understanding the molecular basis of G protein-coupled receptor desensitization and trafficking. My postdoc work has made use of several techniques including various mass spectrometry approaches, single particle cryo-EM and single-molecule fluorescence spectroscopy. In July 2024 I will join the University of Colorado, Anschutz Medical Campus, as an Assistant Professor in the Department of Biochemistry and Molecular Genetics. Besides research, I am passionate about teaching, science communication and making research more inclusive and welcoming. Outside of the lab, I am an avid bike racer, an occasional cycling coach, and I enjoy spending time with my wife, son, and Bernedoodle." Dr. John Janetzko on the web Stanford University Stanford Medicine Google Scholar Personal Website ResearchGate LinkedIn Twitter Dr. GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Quick recap In their conversation, Yamina and John discussed crafting social media posts for John's scientific content. They also shared their respective backgrounds and future plans, with John planning to start his own lab at the University of Colorado School of Medicine. John shared his journey into science, from his interest in creative fields to his involvement in the Chemistry Olympiad and subsequent academic pursuits. The conversation also touched on the challenges of applying for academic positions in the US, the importance of adaptability in one's career, and the potential benefits of networking and mentorship. Next steps • Yamina will share ideas on supporting John's new academic position after the recording stops. • John will prioritize getting feedback from people outside his lab to structure his job seminars. Summary Social Media Post Crafting for GPCRs Yamina and John discussed crafting social media posts for John's scientific content. Yamina emphasized that the content should be kept in a PG-13 context and be scientifically related to GPCRs. John expressed his comfort in sharing his stories and agreed to follow Yamina's guidelines. They also discussed their respective backgrounds and John's future plans to start his own lab at the University of Colorado School of Medicine. John shared his journey into science and his initial interest in creative fields. John's Chemistry Olympiad Journey John shared his experiences in high school, where he developed a keen interest in advanced physics and math curriculum. He participated in various academic competitions, including math, physics, and chemistry contests. John explained that he was drawn to chemistry because it allowed him to build things in his mind and design them. He discovered the National Chemistry Olympiad and was selected to attend a provincial training camp at the University of Toronto. This led to his participation in the National Training Program in Quebec City and his selection to represent Canada at the Chemistry Olympiad in Moscow, Russia. John also mentioned his university application process, which was less stressful than the US system. Yamina shared her own experiences with applying to universities in Canada and the US. John's Chemistry Olympiad and GPCR Journey John shared his experience with the Chemistry Olympiad program, highlighting its rigorousness and advanced content that exceeds typical high school curriculums. He also reflected on his journey from his early involvement in a university chemistry lab to his current interest in graduate school, inspired by the innovative approach of using chemistry to understand and build tools for biology. Yamina sought clarification on John's involvement with GPCRs, but the transcript ended before he could respond. John's Scientific Journey and Lab Collaboration John discussed his scientific journey, starting with a project in Suzanne Walker's lab focusing on the essential mammalian protein O-GlcNAc transferase. He then moved to Dan's lab where he met Suzanne and her project. Towards the end of his PhD, John became interested in understanding how proteins operate as large macromolecular machines and decided to work on memory proteins. He chose Brian's lab due to his interest in studying conformational changes. John shared his experience of reaching out to and securing a position in Brian's lab. He detailed his initial email contact, the subsequent Skype meeting, and the in-person visit that led to his acceptance of the position. John also discussed the potential complications that arose when his then-girlfriend, now wife, was applying for residencies. Ultimately, John did join the lab after his girlfriend successfully matched at Stanford. John explained the collaborative culture in Brian's lab, where individuals are encouraged to pursue projects aligned with their interests. He shared his experience working on a project involving receptor kinases and collaborating with other postdocs in the lab to develop assays and improve the biochemistry of certain targets. The conversation emphasized the importance of diverse backgrounds and skill sets in tackling complex challenges and finding solutions. Academia vs. Industry: Career Progression Discussion Yamina and John had a detailed discussion about the prospects of staying in academia versus transitioning to biotech or industry. John shared his thoughts about the great science happening in other sectors and how the decision largely depended on the opportunities presented. Yamina agreed and sought advice from John on career progression in academia. John suggested building milestones and landmarks into a postdoc, such as applying for funding opportunities, and getting diverse feedback to effectively present work. The conversation ended with Yamina asking when a postdoc should start considering their next steps in their career. Academic Position Applications and Transition Preparation John and Yamina discussed the extensive process of applying for academic positions in the US. John suggested starting preparations a year to two years ahead due to the time needed to develop ideas, write proposals, and get feedback. They also highlighted the need for mentorship and networking in finding job opportunities. Yamina questioned whether universities adequately prepare postdocs for the transition to industry or academia, suggesting a detailed manual or guide might be helpful. Both agreed on the importance of adaptability, as unexpected situations like the Covid-19 pandemic can affect the job searching process. John shared his experiences, stating that he submitted approximately 35 to 40 applications and that the interview process is time-consuming. Career Choices and Support in Academia John shared his positive experiences from job interviews and forming friendships with colleagues at various institutions. He also discussed the challenges of choosing between job offers, including considering his wife's career, her family's location in Denver, and other factors like monetary package and colleagues. John emphasized that negotiating salary is often not possible due to strict regulations. Yamina suggested having round tables to discuss these topics. John then reflected on his career, sharing key moments of realization in his scientific work and his upcoming transition out of his lab. The conversation concluded with both John and Yamina expressing a desire to support the academic community in various ways. Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Terry Kenakin About Dr. Terry Kenakin After obtaining a BSc in chemistry at the University of Alberta Edmonton Canada, Terry received his Ph.D. in Pharmacology from the University of Alberta, Department of Chemistry, Canada. Dr. Kenakin then moved to the UK, where he did a post-doctoral fellowship in University College London with Sir James Black. His next stop took him to Burroughs-Wellcome (BW) in Research Triangle Park (RTP) in North Carolina USA. After 7 years at BW, Dr. Kenakin joined Glaxo Inc in RTP where he remained for 25 years through iterations of Glaxo Inc, GlaxoWellcome , and finally GlaxoSmithKline . Since 2011, Terry works at the Department of Pharmacology at the University of North Carolina School of Medicine Chapel Hill NC. His interests are in receptor pharmacology, allosteric protein function, and drug discovery. Dr. Terry Kenakin on the web LinkedIn UNC Department of Pharmacology Amazon ResearchGate Pubmed . Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Lauren M. Slosky About Dr. Lauren M. Slosky Lauren Slosky is an Assistant Professor in the Department of Pharmacology and a member of the Medical Discovery Team on Addiction, a multidisciplinary initiative within the University of Minnesota’s Medical School to advance research and treatment in the field of drug addiction. Dr. Slosky’s research is focused on understanding how neuropeptide G protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic benefit. Dr. Slosky was awarded a B.S. with honors in Molecular and Cellular Biology and Psychology from The University of Arizona in 2011. She received a Ph.D. in Medical Pharmacology from The University of Arizona in 2015 and completed a postdoctoral fellowship in the laboratory of Dr. Marc G. Caron at Duke University. Dr. Slosky opened her laboratory at the University of Minnesota Medical School in 2021. While a postdoctoral fellow, Dr. Slosky characterized a new class of β-arrestin biased allosteric modulators (BAMs) for the neurotensin receptor 1. These ligands stimulate receptor β-arrestin recruitment without activating canonical G protein signaling. Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects characteristic of balanced receptor activation. Because BAMs engage less well-conserved allosteric sites and exert pathway-specific effects on receptor signaling, they are exciting tools for linking distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics. This work was made possible by the optimization of longitudinal intravenous self-administration paradigms for genetically modified mice. Integrating GPCR biology, behavioral pharmacology, and systems neuroscience approaches, the Slosky Lab is now working to understand how the principles of receptor allosterism and functional selectivity can be leveraged in the development of safe and effective treatments for stimulant and opioid use disorders. Dr. Slosky’s work has been recognized through several travel and research awards, including the William James Psychology Award, the Hank Yamamura Endowed Fellowship in Pharmacology, an NIH F32 Postdoctoral Fellowship, and an NIH K99/R00 Pathway to Independence Award. In addition to research, Dr. Slosky is passionate about training the next generation of scientists and increasing diversity, equity, and inclusion in science. An advocate for trainees at all levels, she served as Service Chairperson and Interim President of the Duke University Postdoctoral Association. She is currently a faculty trainer for the University of Minnesota's MS and Ph.D. programs in Pharmacology, Graduate Program in Neuroscience, and Life Sciences Summer Undergraduate Research Program and is working to build relationships with key stakeholders through institutional and community service. Dr. Lauren M. Slosky on the web Twitter University of Minnesota Department Page LinkedIn Google Scholar PubMed Research Gate Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Peter Robert Banks About Dr. Peter Robert Banks Peter Banks is currently the Scientific Director at BioTek Instruments , now a part of Agilent . His responsibilities include the management of the company’s applications team and providing scientific guidance to the senior management team on new technology and emerging trends impacting life sciences. Before joining BioTek in 2008, Banks was employed by PerkinElmer for a decade. These roles included management of PerkinElmer’s BioPharma R&D program and Chair of the company’s Scientific Advisory Board. Prior to experiences at PerkinElmer and BioTek, Banks was an Assistant Professor in Analytical Chemistry at Concordia University, Montreal, Canada from 1994 to 1998. Dr. Peter Robert Banks on the web LinkedIn Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Graham Ladds About Dr. Graham Ladds Graham studied Biochemistry at the University of Birmingham before completing a Ph.D. in yeast pheromone signaling at Warwick. He continued to work at Warwick as a post-doc studying pro-hormone convertases before securing a 5-year independent fellowship funded through the NHS. This project enabled him to return to his interest in GPCRs. He progressed through the ranks at Warwick to become an Associate Professor before leaving in 2015 to join the Department of Pharmacology at Cambridge, where he is also a Fellow of St John’s College. In 2020, he was promoted to a Readership/Professor in Receptor Pharmacology and was elected a Fellow of the British Pharmacological Society. His research group uses a combination of pharmacological investigations and mathematical modeling to study factors that control agonist bias at GPCRs. These investigations have enabled him to foster strong collaborations with the pharmaceutical industry (GSK, Takada, and Firmenich) which have recently been enhanced through him being awarded a Royal Society Industry Fellowship to collaborate with AstraZeneca . Dr. Graham Ladds on the web Twitter ResearchGate LinkedIn Google Scholar PubMed Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Inês Pinheiro, Monserrat Avila Zozaya & Yamina Berchiche About Inês Pinheiro PharmD by training and Ph.D. candidate in Hartley's lab at the University of Geneva. As a young researcher fascinated by chemokine receptors, molecular pharmacology, drug discovery, and immuno-oncology. Inês Pinheiro on the web LinkedIn University of Geneva Twitter Dr. GPCR Ecosystem About Monserrat Avila Zozaya I am a cell biologist interested in studying GPCRs, especially adhesion GPCRs. Motivated by my scientific passion, I recently started a postdoctoral fellowship to study the role of GPCRs in the mechanisms of pain and its comorbidities. Monserrat Avila Zozaya on the web Antony Boucard Lab Dr. GPCR Ecosystem About Yamina Berchiche Dr. Yamina A. Berchiche is the founder of Dr. GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors (GPCRs), that control virtually everything in the body, as drug targets. The mission of Dr. GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the field and providing exposure to scientists through the Dr. GPCR podcast. Dr. Berchiche obtained her Master’s and Ph.D. in Biochemistry at the University of Montreal in Canada before training at The Rockefeller University in New York and the National Institutes of Health in Bethesda, Maryland. She developed expertise over the past two decades studying structure/function relationships of GPCRs using live-cell bioluminescence resonance energy transfer (BRET). Her work focused on chemokine receptors, members of the GPCR family that control cell movement in the body. Yamina Berchiche on the web Website LinkedIn Facebook Twitter ResearchGate PubMed Google Scholar Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Dr. Amynah Pradhan on why mu opioids worsen migraine, why delta agonists may relieve it, and how chronic disease states rewrite drug discovery. << Back to podcast list Strategic Partner(s) Amynah Pradhan: The Delta Opioid Receptor and the Migraine Paradox Chronic migraine sits at a peculiar crossroads in opioid pharmacology: sustained mu opioid receptor activation is a well-documented driver of medication-overuse headache, while preclinical evidence points to delta opioid receptor agonism as a candidate to relieve the same disorder. Dr. Amynah Pradhan's lab at the University of Illinois at Chicago has spent years pulling apart that asymmetry — combining mouse models of chronic migraine, cortical spreading depression, and opioid-induced hyperalgesia with peptidomic screens and conditional genetics to ask where the two receptors diverge anatomically, pharmacologically, and in the chronic disease state. The work sits inside a larger argument Dr. Pradhan returns to often: that organisms in chronic pain are fundamentally different biological systems than naïve ones, and that drug discovery fails when it pretends otherwise. For her, this line of work is also personal — the delta opioid receptor has been her scientific focus for nearly two decades, through failed clinical trials in depression and pain, and migraine may finally be where it finds a clinical home. About the Guest Dr. Amynah Pradhan is Associate Professor of Psychiatry at the University of Illinois at Chicago, where her lab studies opioid receptor biology in the context of headache disorders, chronic pain, and their comorbid emotional states. She trained in pharmacology at McGill University with Paul Clarke and completed postdoctoral work at AstraZeneca, with Brigitte Kieffer in Strasbourg, and with Chris Evans at UCLA. Her research integrates behavioral pharmacology, ligand-directed signaling, and mouse models of migraine, and has become central to the small community of basic pharmacologists working inside the headache field. Scientific Themes of the Conversation The mu/delta asymmetry in migraine — why two receptors in the same family produce opposite clinical outcomes Chronic disease states as fundamentally altered biological systems — and what that means for drug discovery Ligand-directed signaling and receptor trafficking — how internalization shapes tolerance and adverse effects The emotional circuitry of chronic pain — and the kappa opioid / dynorphin link The unfinished GPCR frontier — PACAP, CGRP, and the persistent antibody problem Career mobility through collaboration — how a headache neurologist redirected two decades of work Key Insights from the Conversation The yin-yang that organizes the lab. Mu opioid agonists, in chronic use, exacerbate migraine and drive medication-overuse headache. Delta opioid agonists appear to relieve the same symptoms — pain, negative affect, and aura-related signs in preclinical models. Dr. Pradhan treats the contrast not as a side story but as the organizing question of her work. Chronic states are not scaled-up acute states. One of Dr. Pradhan's recurring arguments is that the organism in a chronic disease state is fundamentally altered, and that drug candidates fail in clinical trials partly because they are validated in naïve animals that do not resemble the patients they will eventually treat. Internalization is a design choice, not a side effect. Earlier work in her career showed that high-internalizing delta agonists drive receptor downregulation and tolerance, while low-internalizing agonists uncouple the receptor from ion channels without losing it. The ideal delta agonist, by her account, would be non-internalizing, brain-penetrant, long-half-life, and directed at forebrain circuits where emotional salience of pain lives. Delta agonists may finally have a disease. After failed trials in depression and pain, Dr. Pradhan argues that migraine — with its emotional comorbidity, its anatomical overlap with delta receptor expression, and its distinctive pain mechanisms — may be the clinical home the compound class has been looking for. The conviction is quiet but deeply held. The antibody problem is keeping a field from basic answers. Her "bugaboo": we still do not know reliably where many GPCRs live — which cell type, which compartment, surface versus intracellular — because antibodies for the family are widely unreliable. For a pharmacologist, the resolution problem sits upstream of every other question. A single collaboration can redirect a career. Her move from pure opioid pharmacology into migraine came from sharing a building with neurologist Andrew Charles at UCLA. She treats this as a generalizable lesson for junior scientists: openness to collaboration is not decorative — it is how fields get rewired. The invisible labor of being the only one in the room. Toward the end of the conversation, Dr. Pradhan turns to the structural weight carried by women and scientists of color in academia — the cumulative load of committee service, mentorship, and representation — and argues that real support requires institutions to account for it, not just request it. Episode Timeline Timestamps were generated using AI for readability. 00:00 Introduction 01:13 From McGill to migraine — a path through four labs 04:19 Why mu worsens migraine and delta relieves it 09:27 What chronic dosing does to the receptor — tolerance, internalization, downregulation 14:17 Designing the delta agonist she wants 17:30 The emotional circuitry of chronic pain — and the kappa link 22:22 CGRP, PACAP, and why GPCR drug discovery is not out of runway 28:54 Biased ligands after the hype cooled 34:08 How you measure migraine in a mouse 40:44 Three aha moments — and why delta agonists may finally have a home 43:28 The hidden cost of being the only one in the room 57:05 What the pandemic did to a mouse colony Selected Quotes "The delta opioid receptor is my baby. I've been working on it for almost 20 years under lots of different contexts." "The organism is fundamentally altered in a chronic disease state. They're not in the same state as they were if they were naïve. Patients didn't come to the doctor to look for drugs because they were feeling fine." "Every person I know who studies G-protein coupled receptors will tell you — the antibodies suck. We're still arguing about where the receptor is. What cell type it's on. Is it on the cell surface? Is it inside the cell? The fact that we can't say that is kind of crazy to me." "Maybe the disease state where delta ligands would really be effective would be in headache disorders — in migraines specifically. Maybe this is where it all comes together." About this episode In this episode of the Dr. GPCR podcast , we meet with Dr. Amynah Pradhan. She is an Associate Professor of Psychiatry at the University of Illinois at Chicago. Amynah did her undergrad research measuring IP3 in airway smooth muscle cells and completed a Ph.D. at McGill University in Canada with Dr. Paul Clarck , where she studied opioid receptors. Her next career step took her to AstraZeneca as a postdoctoral trainee, where she studied animal models of pain and sensory neuron sensitive-receptor. She then returned to academia and worked on opioids as a postdoctoral trainee with Dr. Brigitte Kieffer , where she studied ligand-directed signaling at the delta-opioid receptor. Her career path-defining moment came from a third postdoctoral experience with Dr. Chris Evans at UCLA. Amynah studied how arrestins regulate ligand-directed signaling at delta-opioid receptors, and it is their collaboration with a headache physician-scientist Dr. Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic target to treat headache. Dr. Amynah Pradhan on the web Lab page LinkedIn Twitter Google Scholar PubMed Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Advance your GPCR research with expert-led Masterclasses on pharmacology, efficacy, signaling, and drug discovery. Built for serious scientists. University / Masterclass On Demand Every Masterclass session. Anytime. At your pace. The full recording library of GPCR Masterclass sessions — revisit the science, catch what you missed, and explore topics at the depth they deserve. On-demand recordings are included inDr. GPCR University Try it for 14 days Recording library Explore the Masterclass library Full recordings of every Masterclass session. Filter by category, level, or instructor to find exactly what you need. Filter by Category Filter by Level Filter by Instructor Watch Now Jakob Höppner Subcellular PTH1R Regulation: Lessons from Rare Disease Watch Now Sam Hoare How Signaling Kinetics Shapes GPCR Drug Action Watch Now Kenneth A. Jacobson, Matteo Pavan Structure-Based Design of Modulators of Purinergic GPCRs Watch Now Terry Kenakin Designing with Time: GPCR Ligand Kinetics Watch Now Andrew Tobin How to Build Breakthrough GPCR Programs Watch Now Terry Hebert GPCR Signaling in iPSC-Derived Cardiac Disease Models Watch Now Terry Kenakin Assessing Bias: The Practical Approach Watch Now Terry Kenakin From Body to Benefit: Drug Disposition Watch Now Sudarshan Rajagopal The Spatiotemporal Revolution in GPCR Biology Watch Now Bryan Roth GPCR Molecular Glues: Biased Modulation at the Receptor–Transducer Interface Watch Now Terry Kenakin Unconventional GPCR Ligands Watch Now Terry Kenakin The New Frontier of GPCR Therapeutics 1 2 3 1 ... 1 2 3 ... 3 The scientists Learn from world leaders in GPCR research Every session is led by a recognized expert with decades of experience in GPCR pharmacology and drug discovery. Andrew Tobin University of Glasgow Jakob Höppner Endocrine Unit, Massachusetts General Hospital and Harvard Medical School Marsha Pierce Midwestern University Samuel Hoare Pharmechanics LLC Terry Hébert McGill University Yamina Berchiche Dr. GPCR & Yamina's Corner Bryan Roth UNC Chapel Hill Medical School Kenneth Jacobson NIH Matteo Pavan NIH Sudarshan Rajagopal Duke University School of Medicine Terry Kenakin Terry's Corner How it works? Your library. Your pace. 1 Browse or search Filter by scientific category, instructor, or level. Find the session that matches what you're working on right now. 2 Watch at your pace Full recordings with no time limits. Pause, rewind, revisit. The science is here whenever you need it. 3 Go deeper Join the next live Masterclass to ask your questions directly. The recordings are the foundation — the live sessions are where you go further. Want to be in the room live? Live Masterclass sessions run regularly with interactive Q&A. See what's coming up next. See live sessions → What others are saying Dr. Hoare is very experienced in the field. What came as a pleasant surprise was how didactical and well-thought-out his course was—highly recommended. The really unexpected was that the Q&A sessions reached the highest level—beyond excellent. I am a convert! I will keep Dr. GPCR and the offered resources in my work sphere GPCR researcher Thank you for bringing this course with Dr. Kenakin. I wish Dr. GPCR the best for the sake of promoting more educational opportunities that are sorely needed in the field GPCR researcher The content had enough depth to satisfy the hunger for theory while being full of practical knowledge GPCR researcher The best pharmacology teacher teaming up with the best GPCR community platform to help train and inspire the next generation of scientists. Also super-valuable for those of us learning how to teach pharmacology GPCR researcher Dr. Hoare's extensive and elaborative explanation of the topics at hand was excellent and very digestible. Thoroughly enjoyed learning from him GPCR researcher Dr. Kenakin is a leading expert in the field. Aside from his vast experience in drug development, not to mention his extensive publication record, Dr. Kenakin is a masterful teacher and communicator. GPCR researcher About the GPCR Masterclass What is a GPCR Masterclass? The GPCR Masterclass is a live scientific discussion with a leading expert in GPCR pharmacology, receptor biology, or drug discovery. Sessions focus on research questions, experimental interpretation, and emerging challenges in GPCR science. Are the sessions live or recorded? Who should join? Can I watch sessions later if I miss the live event? Can I watch sessions later if I miss the live event? How do I fit this in my schedule? What makes the Masterclass different from reading papers or textbooks? What happens during the live discussion? 200+ sessions are waiting for you inside University The full on-demand library, plus live Masterclasses, premium intelligence, jobs, events, and a community of GPCR scientists — all in one place. See what it feels like... Try University for 14 days — $50

<< Back to podcast list Strategic Partner(s) Dr. Pierre Eftekhari About Dr. Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development. have been engaged in GPCR cellular and clinical pharmacology as scientist or PI in neonatal lupus, Cardiomyopathy, hypertension, chagas disease. I have participated and initiated methodologies for development of pharmacologically active anti-GPCR antibodies like agonist, antagonist, inverse agonist or blocker. During my Scholar period I have published or contributed in 38 published scientific work mainly in the field of immunology and pharmacology of GPCR. The majority of my research is concentrated on rhodopsin family with a few works on metabotropic receptor. Since the creation of Inoviem scientific in Nov. 2011 by myself we have been regularly working with GPCRs for our pharma and biotech clients. The latter mainly in target deconvolution and patient stratification." Dr. Pierre Eftekhari on the web Inoviem Scientific ResearchGate LinkedIn Twitter Dr. GPCR Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Discover our comprehensive Trademark Policy designed to protect the integrity and uniqueness of Dr. GPCR Ecosystem. Learn more on our website today. Trademark Policy Dr. GPCR, Corp (“Dr. GPCR”) provides its Service to you through our websites referred to as Dr. GPCR, Ecosystem.DrGPCR.com, DrGPCR.com. If Dr. GPCR approves your request to use any Dr. GPCR trademarks, logos, web pages, screenshots, or other distinctive features ("Dr. GPCR Brand"), you agree to be bound by the following terms and conditions (the "Agreement"). You agree to comply with the Guidelines for Third-Party Use of Dr. GPCR Brand Features. So long as you do so, and provided that Dr. GPCR expressly approves your permission request, Dr. GPCR grants you a non-transferable, non-exclusive, royalty-free, limited license to use the Dr. GPCR Brand Features set forth in your corresponding Permission Request Form for the sole purpose and only for the materials set forth therein. Any use of the Dr. GPCR Brand Features must be accompanied by a notice that clearly indicates that the Dr. GPCR Brand Features are trademarks or distinctive brand features of Dr. GPCR Corp. Dr. GPCR reserves the right in its sole discretion to terminate or modify your permission to display the Dr. GPCR Brand Features and to take action against any use that does not conform to these terms and conditions, infringes any intellectual property or other rights, or violates applicable law. Except as set forth above, nothing herein grants or should be deemed to grant to you any right, title, or interest in or to the Dr. GPCR Brand Features. Your use of the Dr. GPCR Brand Features will inure to the benefit of Dr. GPCR. You agree not to challenge or assist others to challenge the Dr. GPCR Brand Features (except to the extent such restriction is prohibited by applicable law), and you agree not to register or attempt to register any domain names, trademarks, trade names, or other distinctive brand features that are confusingly similar to those of Dr. GPCR. The Dr. GPCR Brand Features are provided "as is" and Dr. GPCR disclaims any warranties either expressed or implied by law regarding the Dr. GPCR Brand Features, including warranties of non-infringement. Furthermore, because you are not being charged for use of the Dr. GPCR Brand Features, in no event shall Dr. GPCR be liable to you for the subject matter of this Agreement under any theory of liability including for any direct, indirect, incidental, special, consequential, punitive, exemplary or other damages arising out of this Agreement or the use of the Dr. GPCR Brand Features. This limitation shall apply even if Dr. GPCR was or should have been aware or advised of the possibility of such damages and notwithstanding any failure of the essential purpose of any limited remedy stated herein. Some states do not allow the exclusion of implied warranties or limitation of liability for incidental or consequential damages, so the above limitations or exclusions may not apply to you. You may not assign your rights or delegate your obligations under this Agreement without Dr. GPCR's prior written consent. This Agreement is not intended to benefit, nor shall it be deemed to give rise to, any rights in any third party. These Terms and Conditions shall be governed by the laws of the State of New York without regard to the principles of conflicts of law. Unless otherwise elected by Dr. GPCR in a particular instance, Customer hereby expressly agrees to submit to the exclusive personal jurisdiction of the federal and state courts of New York County, New York. The parties are independent contractors. Neither party shall be deemed to be an employee, agent, partner, or legal representative of the other for any purpose, and neither shall have any right, power, or authority to create any obligation or responsibility on behalf of the other. The waiver by FindYooour, LLC of a breach of any provision hereof shall not be taken or held to be a waiver of the provision itself. If any provision of this Agreement is held by a court of competent jurisdiction to be contrary to law, such provision shall be changed and interpreted so as to best accomplish the objectives of the original provision to the fullest extent allowed by law and the remaining provisions of this Agreement shall remain in full force and effect. This Agreement, the Guidelines for Third-Party Use of Dr. GPCR Brand Features, and the Permission Request Form constitute the entire agreement between the parties regarding the subject matter of this Agreement. If you’ve found a website that uses a Dr. GPCR trademark inappropriately, we’d like to hear about it. Report inappropriate use of a D. GPCR trademark. Buttons And Badges The Dr. GPCR buttons and badges are publisher integration points that applications, websites, and other services (collectively, "Publishers") can add to websites so that Dr. GPCR users can connect to and share on Dr. GPCR. These include: - Dr. GPCR Badge and Follow button This button is a means for Publishers to enable Dr. GPCR users to quickly follow the Publisher's Business Page directly via a widget on the Publisher's website. After clicking the button, the user indicates to follow that Publisher. - Dr. GPCR Share button The share buttons provide a lightweight way for Publishers to invoke a Dr. GPCR Share dialog and can be implemented using a Dr. GPCR icon. The policies below, as well as the Dr. GPCR Buttons and Badges guidelines, the Dr. GPCR Terms of Service, govern a Publisher's use of the Dr. GPCR buttons. Buttons And Badges Policy Publishers may not attempt to discover the identity of a Dr. GPCR button user unless the user consents to share his or her identity with the Publisher via a Dr. GPCR-approved authorization procedure. This prohibition includes identifying users by correlating Dr. GPCR button reporting data from Dr. GPCR with Publisher data. Publishers may not sell or transmit to others any data about a user related to the user's use of any Dr. GPCR button. For the avoidance of doubt, this prohibition includes, but is not limited to, any use of pixels, cookies, or other methods to recognize users' clicks on a Dr. GPCR button, the data of which is then disclosed, sold, or otherwise shared with other parties. Publishers must disclose clearly any data collection, sharing, and usage that takes place on any site, app, or other property as a consequence of using Dr. GPCR buttons. To comply with this disclosure obligation with respect to Dr. GPCR's use of data, publishers have the option to display a prominent link to How Dr. GPCR uses data when you use our partners’ sites or apps. Publishers may not alter or obfuscate a Dr. GPCR button, and Publishers may not associate a Dr. GPCR button with advertising content, such as putting the Dr. GPCR Button on or adjacent to an ad, or placing ads in shared content, unless authorized to do so by Dr. GPPCR. Publishers also may not place in shared content any text, image, or other content that violates the Dr. GPCR User Content and Conduct Policy. For buttons that may be rendered by the Publisher, such as the Sharing link, the Publisher must use only the official Dr. GPCR-provided icon or a plain text and link combination. In either case, Publishers must not mislead users as to the purpose of the link. Publishers may not direct users to click a Dr. GPCR button for purposes of misleading users. Publishers may not promote prizes, monies, or monetary equivalents in exchange for Dr. GPCR button clicks. For the avoidance of doubt, Publishers may direct users to a Dr. GPCR button to enable content and functionality. When a Publisher directs users to a Dr. GPCR Button, the button action must be related to the Publisher or the Publisher's content. For the Share button, the content or functionality that is enabled for the user must also be accessible to any of the user's social connections who also enable it. FindYooour may analyze Publishers' use of a Dr. GPCR button including to ensure Publishers' compliance with these policies and to facilitate Dr. GPCR development of Dr. GPCR Buttons. By using a Dr. GPCR button, Publishers give Dr. GPCR permission to utilize an automated software program, often called a "web crawler," to retrieve and analyze websites associated with a Dr. GPCR button. If Publishers' sites or services are directed at children under 13 or Publishers have actual knowledge that users of their site or service are children under 13, then Publishers must comply with the US Children's Online Privacy Protection Act when using any Dr. GPCR buttons. Buttons And Badges Guideline These guidelines provide you with the design specification for various Dr. GPCR buttons and badges. You can use these assets on your app (website or mobile app) without pre-approval provided you follow these basic guidelines. Use of Dr. GPCR brands in ways not expressly covered by this document is not allowed without prior written consent from Dr. GPCR. Button use must also be in line with this Button's Policy. Dr. GPCR badge, share and follow button branding guidelines Adding a Dr. GPCR badge to your website, email, or marketing campaign makes it easy for fans to follow you, or join your community. Similarly, the compact. The Share button allows visitors to easily share your content with their circles. We prefer that you use the MagyarBusiness.org badge, Share button, and Follow button in their provided formats. Dr. GPCR icon as a button or badge: In certain situations, you might want to use the Dr. GPCR icon to enable users to share content to Dr. GPCR or to link to your Page so that users can follow you. You can do this so long as the context makes it clear what action will be taken when the user clicks on the icon. In addition, the icon must adhere to the Dr. GPCR icon guidelines below, including color scheme, styling, and so forth. Dr. GPCR Brand Permissions All of our brand features are protected by applicable trademark, copyright and other intellectual property laws. If you would like to use any of our brand features on your website, in an ad, in an article or book, or reproduce them anywhere else, or in any other medium, you'll need to receive permission from Dr. GPCR first. And please note that the user experience with all our products should never be altered. Using the Dr. GPCR logo The Dr. GPCR logo is the most prominent visual representation of our brand, and we want it to be used in the right way. We generally do not approve the use of our logo in third-party marketing materials. This includes online and offline advertising collateral such as: Merchandise featuring the Dr. GPCR logo We cannot grant permission for the use of Dr. GPCR Logo in different marketing materials, such as a new T-shirt design, a toy, software packaging, or other products. Screenshots of Dr. GPCR products You don't need our permission when you want to use an unaltered screenshot of our Website (DrGPCR.com or Ecosystem.DrGPCR.com) or the search results page for instructional or illustrative purposes. This applies to print (book, magazine, journal, newspaper) or digital (webpage, DVD, CD, post) formats. Please see below for exceptions to this rule for some of our other products. Don’t use unaltered screenshots of the Dr. GPCR Websites. When we say "unaltered", we mean no superimposed graphics, photos, or ad copy on the screenshot and no changes to the way our product looks. We also don't give permission for advertisers to use Dr. GPCR pages in connection with advertising products or services (for instance, showing a top ranking on Dr. GPCR search result page). We ask that you put the following tagline beneath any image featuring a Dr. GPCR product screenshot or data: Note: Dr. GPCR and the Dr. GPCR logo are registered trademarks of FindYooour LLC., used with permission. Use of trademarks Our trademarks are valuable assets, and we want to ensure that our users and partners use them correctly. These trademarks include the Logo, Buttons, Badges, Website Design, and other pictures and graphic designs owned and created by Dr. GPCR How to use You may use our trademarks to accurately refer to our products or services, as long as such references are appropriate and consistent with our trademark guidelines. You may use only approved versions of our marks. Please follow all of the general trademarks. The trademark usage guidelines apply even to marks that were previously (but are no longer) used in connection with our products. How not to use You may not use, incorporate, or combine any of our trademarks into a third-party brand name, product name, business name, trade name, or slogan. You may not use any of our marks in a way that suggests you are endorsed by or affiliated with Dr. GPCR or our products. For example, you may not use our marks: In domain names As app icons or featured in an app As the most prominent elements on your website On physical merchandise, promotional materials, business cards or business stationery In product reviews Please do not modify or mimic our marks. Please read carefully our Legal Policies and Disclaimers to understand how Dr. GPCR conducts business Affiliate Policy Content and Conduct Policy Content Guidance Privacy Policy Terms and Conditions Trademark Policy

Need help? Submit a problem! Get detailed information about incidents and find solutions. Join us today! Report an Incident Thank you for taking the time to report any incidents or issues you are experiencing with our site. Your comments will help us improve and refine the Ecosystem. Who is submitting this incident? First Name Last Name Email Details about this incident Please describe your concern Link to the page where you experienced difficulties Please feel free to upload screen shots or short videos of your concern. Upload File Upload supported file (Max 15MB) Submit Thanks for submitting!

Dr. Bryan Roth on the DARPA-funded effort to design a non-psychedelic psychedelic for depression — and why the real bottleneck in GPCR drug discovery is the biology, not the chemistry. << Back to podcast list Strategic Partner(s) Bryan Roth: Inside the DARPA Bet on a Non-Psychedelic Psychedelic Psilocybin is in Phase 3 trials for depression, and the early signal is striking — a single dose followed by months of remission. The therapeutic mechanism, however, is inseparable from the psychedelic experience itself, and not every patient can or should take a psychedelic. This raises one of the most consequential questions in current GPCR pharmacology: can biased signaling at the serotonin 2A receptor decouple the therapeutic effect from the trip? In this conversation, Dr. Bryan Roth describes the DARPA-funded effort his lab is leading to answer that question through structure-guided drug discovery, biased ligand design, and high-throughput functional assays. The discussion ranges across four decades of receptor pharmacology — from the era when the field debated whether opioid receptors were even proteins, to the cryo-EM-driven structure-function loops that now turn over in three weeks. Dr. Roth is unusually candid about what drug discovery against GPCRs actually requires, why most hypotheses still fail at the indication rather than the chemistry, and why a relative's psychotic break when he was five years old set the trajectory that eventually led him here. About the Guest Dr. Bryan Roth is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine. He earned his MD and biochemistry PhD at St. Louis University and trained in pharmacology at NIH and in molecular biology and psychiatry at Stanford. His lab works on serotonin, dopamine, and opioid receptor structure, function, and drug discovery, with a particular focus on neuropsychiatric disease. He invented DREADD technology, leads the NIH Psychoactive Drug Screening Program, and has contributed to structural and pharmacological characterization of dozens of GPCRs. Scientific Themes of the Conversation Biased agonism at the serotonin 2A receptor and the pursuit of a non-psychedelic psychedelic Structure-guided GPCR drug discovery in the cryo-EM era Why drug discovery bottlenecks are biological, not chemical Polypharmacology for complex neuropsychiatric disease Functional assay design — BRET, Tango, and what each captures The historical evolution of receptor pharmacology, from radioligand binding to atomic-resolution structure Key Insights from the Conversation The bottleneck in GPCR drug discovery is the indication, not the chemistry. Dr. Roth is direct about this: with sufficient medicinal chemistry resources and modern assays, you can make a biased ligand for almost any pathway. What you usually can't do is know which pathway, in which disease, will actually be therapeutic. The hypothesis is what fails. Every GPCR is probably good for something — and we mostly don't know what. This is a quiet conviction Dr. Roth has held for years. It reframes the field's task from finding good targets to understanding the biology well enough to connect targets to indications, a problem he believes will take decades more. A single-target drug may be the wrong goal for complex disease. Clozapine, the most effective antipsychotic, hits at least fifty targets. For schizophrenia and other neuropsychiatric conditions, the genetic landscape may simply be too complex for one-receptor drugs to win. The future, Dr. Roth argues, belongs to designed polypharmacology. The DARPA non-psychedelic psychedelic project is real, early, and moving fast. The premise: psilocybin's therapeutic effect on depression is now well documented, but it is locked to the psychedelic experience. The bet is that biased ligands at the serotonin 2A receptor can separate the two. Six weeks in, structures are turning over and chemistry is iterating. Sometimes a discovery validates itself overnight in ways you didn't sanction. Dr. Roth's lab identified salvinorin A as a kappa opioid receptor agonist. The internet seller who supplied the compound disagreed, took naloxone, smoked salvia to disprove it, and emailed back the next morning conceding the point. A reminder of what scientific certainty sometimes looks like outside the lab. The "you'll never make it" verdict can be wrong, repeatedly. A famous scientist at Stanford and an NIH program officer both told Dr. Roth, in different years, to give up basic science. He didn't. The arc from a lab "about as big as your car" at Case Western to leading a thirty-person GPCR lab at UNC is worth sitting with — particularly for early-career scientists who feel the same verdict closing in. BRET captures the initial event; second messengers can mislead you. For analytical work on biased ligands, Dr. Roth's lab leans heavily on BRET-based G protein and arrestin assays because they're relatively insensitive to receptor reserve and capture coupling close to the receptor. Tango and calcium assays are reserved for screening, where false negatives are the real cost. Episode Timeline 00:00 Introduction 02:03 Witnessing a psychotic break at age five 05:00 The visiting professor's lecture that sealed it: receptors 06:30 When the field debated whether opioid receptors were even proteins 11:31 The "dumb luck" of starting on serotonin receptors at NIH 16:43 Studying functional selectivity for the Navy in 1987 22:50 "You're never going to make it as a basic scientist" 28:13 The lab the size of a car at Case Western 35:26 The DARPA project: a non-psychedelic psychedelic for depression 38:21 "I am not uncertain" — the data Bryan won't talk about yet 47:13 Why BRET captures what second-messenger assays miss 51:01 Why most GPCR drug hypotheses fail — and it isn't the chemistry 55:38 Fifty targets, one drug: clozapine and complex disease 01:03:06 The kappa receptor validated in a human trial overnight 01:06:00 Solving the lab's first GPCR structure 01:08:33 Advice for junior scientists who don't have ten Nature papers Timestamps were generated using AI for readability and may shift slightly relative to the final edited cut. Selected Quotes "Every GPCR is good for something, basically. If we make a drug against any GPCR, it's going to be good for some disorder. We don't know what that is. That's the problem." "The reason that so many things fail is not because a chemist didn't do their work, but because the hypothesis was basically wrong. The idea was, if we make a drug against this target, it will be useful in this disease. And that just may be the wrong hypothesis. It typically is the wrong hypothesis." "I was too stupid to listen to him, basically, is what I tell people." "Find the thing that you're really, really passionate about. Find that. And don't pay so much attention to the outcome. It's the doing that's more important." About this episode Dr. Bryan Roth is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine. After receiving his MD and Ph.D. in Biochemistry from St. Louis University in 1983, he subsequently trained in pharmacology (NIH), molecular biology, and psychiatry at Stanford. Bryan leads a $26.9 Million project to create better psychiatric medications, among other things. But, it wasn’t always this way. Bryan got fascinated with receptors after attending the lecture of a visiting professor on neurotransmission while in college in Montana, where he is from. He was determined to work on psychiatric disorders and persevered even when he was told several times he would never make it as a basic scientist and would never publish anything important. Join me and learn more about Bryan and his work. Dr. Bryan Roth on the web UNC School of Medicine / Pharmacology Roth Lab Roth Leads $26.9 Million Project to Create Better Psychiatric Medications LinkedIn Bryan Roth on Twitter Roth Lab on Twitter Google Scholar Pubmed Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Learn all about the content guidelines for Dr. GPCR Ecosystem website. Get the information you need to create engaging and impactful content. Content and Conduct Policy Dr. GPCR, Corp, LLC (“Dr. GPCR”) provides its Service to you through our websites referred to as Dr. GPCR, Ecosystem.DrGPCR.com, DrGPCR.com. We rely heavily on users to report content that may violate our policies. After we are notified of a potential policy violation, we may review the content and take action, including restricting access to the content, removing the content, and limiting or terminating a user’s access to Ecosystem.DrGPCR.com products. Note that we may make exceptions to these policies based on artistic, educational, or documentary considerations or when there are other substantial benefits to the public from not taking action. We respect the freedom of speech. Please note that Ecosystem.DrGPCR.com is specializes in GPCR and related subjects. We occasionally modify these policies, so please check back here for updates. Beyond the guidelines listed below, please note that several products and features may have additional policies and terms; check the provided links for those specific requirements. Responsibility for Your Content You are solely responsible for Your Content, and once published, it may not always be withdrawn. You assume all risks associated with Your Content, including anyone's reliance on its quality, accuracy, or reliability, or any disclosure by you of information in Your Content that makes you personally identifiable. You represent that you own or have the necessary permissions to use and authorize your Content as described herein. You may not imply that Your Content is in any way sponsored or endorsed by Ecosystem.DrGPCR.com. You may expose yourself to liability if, for example, Your Content contains material that is false, intentionally misleading, or defamatory; violates any third-party right, including any copyright, trademark, patent, trade secret, moral right, privacy right, right of publicity, or any other intellectual property or proprietary right; contains unlawful material, including illegal hate speech or pornography; exploits or otherwise harms minors, or violates or advocates the violation of any law or regulation. Our Right to Use Your Content You also give Ecosystem.DrGPCR.com (Website) a perpetual, irrevocable, worldwide, royalty-free, and non-exclusive license to reproduce, adapt, modify, translate, publish, publicly perform, publicly display, distribute, store and create derivative works of the basic listing information about your entity that you provide to your Ecosystem.DrGPCR.com Account (such as the entity name, location, phone number, list of interest, business category, hours, services, product descriptions, text, videos, contents, and website) We may use Your Content in several different ways, including publicly displaying it, reformatting it, incorporating it into advertisements and other works, creating derivative works from it, promoting it, distributing it, and allowing others to do the same in connection with their websites and media platforms ("Other Media"). As such, you at this moment irrevocably grant us worldwide, perpetual, non-exclusive, royalty-free, assignable, sub-licensable, transferable rights to use Your Content for any purpose. Please note that you irrevocably grant the users of the Site and any Other Media the right to access Your Content in connection with their use of the Site and any Other Media. Finally, you irrevocably waive and cause to be waived against Ecosystem.DrGPCR.com and its users any claims and assertions of moral rights or attribution with respect to Your Content. By "use" we mean use, copy, publicly perform and display, reproduce, distribute, modify, translate, remove, analyze, commercialize, and prepare derivative works of Your Content. Ownership Between you and Ecosystem.DrGPCR.com, you own Your Content. We own the Ecosystem.DrGPCR.com Content, including but not limited to visual interfaces, interactive features, graphics, design, compilation, including, but not limited to, our compilation of User Content and other Site Content, computer code, products, software, aggregate user review ratings, and all other elements and components of the Site excluding Your Content, User Content and Third Party Content. We also own the copyrights, trademarks, service marks, trade names, and other intellectual and proprietary rights throughout the world ("IP Rights") associated with the Ecosystem.DrGPCR.com Content and the Site, which are protected by copyright, trade dress, patent, trademark laws and all other applicable intellectual and proprietary rights and laws. As such, you may not modify, reproduce, distribute, create derivative works or adaptations of, publicly display or in any way exploit any of the Ecosystem.DrGPCR.com Content in whole or in part except as expressly authorized by us. Except as expressly and unambiguously provided herein, we do not grant you any express or implied rights, and we retain all rights in and to the Site and the Ecosystem.DrGPCR.com Content. Advertising Ecosystem.DrGPCR.com and its licensees may publicly display advertisements and other information adjacent to or included with Your Content. You are not entitled to any compensation for such advertisements. The manner, mode, and extent of such advertising are subject to change without specific notice to you. Content We make some of the Ecosystem.DrGPCR.com Site Content available to third parties. You may access and use these content in order to display on your personal computer, website, or blog ("Your Site"), provided that (i) your use of the Feeds is for personal, non-commercial purposes only, (ii) your display of the Feed Content links back to the relevant pages on Ecosystem.DrGPCR.com Website's websites, and attributes Ecosystem.DrGPCR.com as the source of the Content, (iii) your use or display of the Content does not suggest that Ecosystem.DrGPCR.com promotes or endorses any third party causes, ideas, websites, products or services, including Your Site, (iv) you do not redistribute the Content, and (v) your use of the Content does not overburden Ecosystem.DrGPCR.com Website’s systems. Ecosystem.DrGPCR.com reserves all rights in the Content and may terminate the Content at any time. Other User Content (including any that may have been created by users employed or contracted by the Ecosystem.DrGPCR.com Website) does not necessarily reflect the opinion of Ecosystem.DrGPCR.com. We reserve the right to remove, screen, edit, or reinstate User Content at our sole discretion, for any reason or no reason, and without notice to you, from time to time. For example, we may remove a review if we believe it violates our Content Guidelines. We have no obligation to retain or provide you with copies of Your Content, nor do we guarantee any confidentiality with respect to Your Content. Illegal Activities Do not use our Services to engage in illegal activities or promote dangerous and illegal acts. Malicious and Deceptive Practices Do not transmit viruses, malware, or any other malicious or destructive code. Do not distribute content that harms or interferes with the operation of the networks, servers, or other infrastructure of Ecosystem.DrGPCR.com or others. Do not use our Services for phishing scams. Hate Speech Our products are platforms for free expression. But we don't support content that promotes or condones violence against individuals or groups based on race or ethnic origin, religion, disability, gender, age, nationality, veteran status, or sexual orientation/gender identity, or whose primary purpose is inciting hatred on the basis of these core characteristics. This can be a delicate balancing act, but if the primary purpose is to attack a protected group, the content crosses the line. Personal and Confidential Information Do not distribute other people’s personal and confidential information, such as credit card numbers, confidential national ID numbers, or account passwords, without their permission. Do not post or distribute images or videos of minors without the necessary consent from their legal representatives. Account Hijacking Do not access another user’s account without their permission. Child Exploitation Do not upload or share content that exploits or abuses children. This includes all child sexual abuse imagery (even cartoon images or videos) and all content that presents children in a sexual manner. We will remove such content and take appropriate action, which may include disabling accounts and reporting to the National Center for Missing & Exploited Children (NCMEC) and law enforcement. Note that this policy may additionally apply to any content uploaded or transmitted through Photos or Videos. If you find any content that you think exploits children in this manner, do not share or comment on such content, even if your intent is to bring it to Ecosystem.DrGPCR.com's attention. Instead, flag the content. If you find content elsewhere on the internet, please contact NCMEC directly. Spam Do not spam, including by sending unwanted promotional or commercial content, or mass solicitations. Do not aggressively follow people or aggressively message people that you do not know. Ranking Manipulation Do not manipulate rankings or relevancy using techniques such as repetitive or misleading keywords or metadata. Sexually Explicit Material Do not distribute sexually explicit or pornographic material. Do not drive traffic to commercial pornography sites. Note that your profile photo cannot include mature or offensive content. For example, do not use a photo that is a close-up of a person’s buttocks or cleavage. Harassment, Bullying, and Threats Do not engage in harassing, bullying, or threatening behavior, and do not incite others to engage in these activities. Anyone using our Services to single someone out for malicious abuse, to threaten someone with serious harm, to sexualize a person in an unwanted way, or to harass in other ways may have the offending content removed or be permanently banned from using the Services. In emergency situations, we may escalate imminent threats of serious harm to law enforcement. Keep in mind that online harassment is also illegal in many places and can have serious offline consequences for both the harasser and the victim. Violence Do not distribute depictions of graphic or gratuitous violence. Impersonation Do not use our Services to mislead or confuse users by pretending to be someone else or pretending to represent an organization you do not represent. Regulated Goods and Services Your content cannot promote regulated goods and services, including but not limited to alcohol, gambling, unapproved supplements, tobacco, fireworks, or weapons. If we receive a complaint that such content violates applicable laws and regulations, we will remove and delete the offending content or account. Contests and Promotions Ecosystem.DrGPCR.com allows contests, sweepstakes, and other promotions ("Promotions") to the extent permitted by law, subject to the following policy requirements and legal terms outlined below. 1. Generating spam or encouraging individuals to engage in spam or abuse is strictly prohibited. Please note that the definition of spam on Ecosystem.DrGPCR.com may develop and change over time, and that Ecosystem.DrGPCR.com reserves the right to determine what qualifies as spam. In order to play a part in helping us fight spam and abuse, we have the following specific requirements for Promotions: 1a. The official rules for your Promotion must include a clear statement that anyone found to have created multiple accounts in order to increase their chances of winning, or anyone who posts entries in excess of an entry limit you have set, will be disqualified from the Promotion. You must set an entry limit for your promotion below a level that is likely to encourage spam. 1b. If you ask participants to use tags and/or hashtags in their Promotion entries, they must be relevant to the kind of content users are posting. For example, do not ask for photos of sunsets with #spaghetti. 2. Promotions should not be used to try to circumvent any applicable terms or policies. 3. Do not run Promotions that offer potential rewards in exchange for sharing content, following a user, mentioning a user (other than the contest creator, sponsor, or an affiliate of the contest creator or sponsor), having other users enter the promotion, or voting in polls. Also, avoid running promotions that encourage users to post unoriginal or repetitive content. 4. Please note that doing a public search (via hashtag or otherwise) may not show every entry or every participant in your Promotion. Accordingly, you should not rely solely on the search feature to view or find all entries or participants in your Promotion. 5. Please note that some Promotion entries may be filtered, hidden, or removed from Ecosystem.DrGPCR.com for spam or quality reasons, or any of our other applicable policies or terms of service. Use of Multiple Accounts Do not create or use multiple accounts to evade our policies or bypass blocks or otherwise subvert restrictions placed on your account. For example, if you’ve been blocked by another user or suspended for abuse, don’t create a replacement account that engages in similar activity. Please read carefully our Legal Policies and Disclaimers to understand how Dr. GPCR conducts business Affiliate Policy Content and Conduct Policy Content Guidance Privacy Policy Terms and Conditions Trademark Policy

Join the Adhesion GPCR Workshop 2024 in Mexico City at CINVESTAV, bringing together researchers to explore the latest in GPCR science. Welcome to the Adhesion GPCR Workshop 2024 , hosted in the vibrant heart of Mexico City at the prestigious venue, CINVESTAV - Centro de Investigación y de Estudios Avanzados del IPN (in English: Center for Research and Advanced Studies of the National Polytechnic Institute). About the venue Cinvestav: Centro de investigación y de Estudios Avanzados del IPN Av. Instituto Politécnico Nacional no 2508 Mexico City, C.P. 07360 Room: Auditorium Arturo Rosenblueth *Have an ID card ready (Passport, Driver's license, etc), as this will be required at the venue entrance Register now to join the exclusive Adhesion GPCR Workshop group and stay updated with all the latest event news. Preliminary Program Layout Date Time Title October 23, 2024 October 24, 2024 October 25, 2024 *Flash Presentations: 10 min *Talks 20 min (15 min+ 5 min questions Everything you need to know about the event Listen to Dr. Antony Boucard and Dr. Yamina Berchiche at the Dr.GPCR Newsletter Meet the Organizers behind the AGPCR24 Antony Boucard Jr, PhD Host and Organizer Cinvestav, Mexico City Yamina Berchiche, PhD Co-organizer Dr. GPCR, Boston Andreína Martín Website & Social Media Coordinator Dr. GPCR, Boston Ivanna Rey Executive Assistant Dr. GPCR, Boston

Discover Media Partner Packages with Dr. GPCR Ecosystem. Amplify your brand, reach a targeted scientific audience, and showcase your organization in the GPCR community. The Yearly Glow Only 12 companies per year are invited to become Yearly Glow partners. This isn't advertising — it's a strategic partnership that puts your brand at the center of the scientific conversations that matter most. 1,400+ GPCR scientists reached 25–50% Newsletter open rate 12 strategic partnerships per year — because quality matters Partner with us Today! Who Media Partnerships Are For? Companies that think in years, not quarters Strategic Media Partnerships are ideal for GPCR-focused companies that want to: Strengthen brand credibility and recognition within the GPCR research community Associate their brand with high-quality science, experts, and long-term ecosystem initiatives Be consistently visible across trusted educational and content platforms Build awareness and trust over time — not chase immediate leads If your primary goal is to drive inbound inquiries or make your services discoverable at the point of need, the GPCR CRO Bank may be a better fit. "Dr. GPCR is the world's largest nonprofit community focused on GPCRs. As a strtegic partner, you'll gain trusted access to an engaged audience of academic researchers, biotech teams, and drug discovery innovators — without having to fight for attention." Why Partner with Dr. GPCR? Featured across our nonprofit platform, trusted by thousands As a media partner, you'll be featured across our nonprofit platform, trusted by thousands of GPCR scientists and biotech professionals. Reach Qualified Researchers Connect with scientists who are actively looking for tools like yours, without the noise of general platforms. Build Trust Develop content that speaks their language and establishes your credibility in the GPCR research community. Join a Curated Ecosystem Become part of a collaborative, curated ecosystem — not just another name on a crowded vendor list. What You Get as Media Partner? Active visibility, not passive placement These touch points are designed to reinforce brand presence and credibility through repeated, trusted exposure — not direct lead generation. Yearly Glow Exclusive Gated Content Premium content assets created in partnership — gated to capture and nurture scientist engagement while contributing genuine value to the community. Strategy Partnership Ongoing strategic collaboration to align visibility initiatives with your goals and the community's needs. Launch Campaigns Strategic campaigns that actively drive scientist awareness and traffic toward your offerings, timed to maximize community attention. Logo Positioning Strategic Partner logos are featured across multiple high-traffic ecosystem pages, creating repeated visual association with trusted GPCR content and resources. Base Package — Included 🎙️ Featured Podcast Episode ✓ Be the guest on a dedicated episode of the Dr. GPCR Podcast ✓ Feature up to 3 team members to share your story ✓ Distributed across podcast platforms and social media ✨ Logo positioning ✓ Strategic Partner logos are featured across multiple high-traffic ecosystem pages, creating repeated visual association with trusted GPCR content and resources. 📣 Social Media Promotion ✓ Engaging posts about your organization ✓ Targeted to GPCR researchers and biotech professionals ✓ Shared on LinkedIn and X (Twitter) 📝 Blog Contributions ✓ Contribute to blog posts on the Dr. GPCR platform as a valued partner ✓ Share insights on product launches, scientific discoveries, or customer stories ✓ Reach a targeted scientific audience with your contributions. 📄 Custom Company Page ✓ Permanent company profile on the Dr. GPCR Ecosystem ✓ Logo, branding, and description of your mission ✓ Contact links and key highlights 📬 Newsletter Visibility ✓ Featured in our highly read weekly newsletter ✓ Tell your story with context, clarity, and purpose ✓ Bonus: Mentioned in podcast intros/outros 👩🔬 Premium Licenses ✓ 10 Scientists Premium Accounts ✓ 3 Non-Scientists Premium Accounts 🎤 Co-Branded Events & Training ✓ Collaborate on webinars and virtual training sessions to showcase your expertise ✓ Host educational events that focus on GPCR research ✓ Engage directly with the GPCR research community through these initiatives 12 per year — a commitment to quality Only 12 Yearly Glow seats are available each year to keep our ecosystem curated, impactful, and community-focused. Every partner deserves dedicated attention, personalized strategy, and genuine integration. This is real selectivity — a reflection of how seriously we take partner quality and community trust. Previous Partners Join these leading organizations Join these leading organizations in the GPCR research ecosystem. Book Book a 30-minute Strategy Call with Yamina Ready to Connect with the GPCR Community? With only 10 spots remaining for 2026... Secure your place in our exclusive media partner program today.

How receptor residence time — not affinity — rescued a CRF drug discovery program, and why a career in GPCR data analysis starts with asking what the math never captured. << Back to podcast list Strategic Partner(s) Sam Hoare: Receptor Residence Time and GPCR Data Analysis For most of GPCR pharmacology's history, affinity was the number that drove decisions. Which ligand binds tightest, ranks highest, earns the most attention in an SAR campaign. But affinity is a snapshot. It tells you how tightly a compound binds at equilibrium — not how long it stays. When Sam Hoare and the CRF receptor team at Neurocrin Biosciences discovered that their lead compound sat on the receptor for seven hours while a failed backup fell off in fifteen minutes, it exposed a variable drug discovery had been systematically ignoring. That discovery became the foundation of a career built on the data most pharmacologists generate but don't analyze. Sam Hoare brings a data analyst's perspective to GPCR pharmacology — one trained in allosteric modulation, sharpened in Class B receptor biology at the NIH, and refined across fifteen years of industrial drug discovery. His current work extends that logic into signaling kinetics: the time dimension in GPCR signaling that labs routinely measure and almost never formally quantify. For Hoare, the unsolved problem isn't the biology — it's the math no one wrote down. About the Guest Sam Hoare is the founder of Pharmechanics , a pharmacology data analysis consultancy. After a PhD on allosteric modulation of dopamine receptors in Philip Strange's UK lab and a postdoc at the National Institutes of Health studying Class B GPCRs, he spent fifteen years at Neurocrin Biosciences working on CRF receptor drug discovery programs that advanced compounds into clinical trials. Hoare now consults for biotech and pharmaceutical clients on GPCR data analysis, receptor binding kinetics, and pharmacological modeling. His independent research focuses on developing accessible mathematical tools for kinetic analysis of GPCR signaling data, including freely available Prism templates and Excel simulators. Scientific Themes of the Conversation Receptor residence time as a determinant of in vivo drug efficacy — and why affinity alone is insufficient Signaling kinetics: quantifying the time dimension of GPCR pharmacology Allosteric modulation and the mathematical foundations of receptor theory Biased agonism and constitutive activity as practical tools in the drug discovery toolbox The tractability of GPCRs as a pharmacological system — assay accessibility, theory, and the generous culture of the field Scientific consulting: translating deep pharmacological expertise into independent problem-solving practice Key Insights from the Conversation 1. The Off-Rate That Saved a Program Standard binding assays showed identical affinity. But when Beth Fleck measured dissociation rates of the CRF receptor radioligands, the compound that worked in vivo stayed on the receptor for seven hours at room temperature. The failed backup fell off in fifteen minutes. The Neurocrin team had to confront an explanation no assay had been designed to find — and then built new SAR campaigns around it. 2. Affinity Is a Snapshot; Time Is the Story Hoare draws a sharp analogy: running pharmacology dose-response experiments for decades without fitting a sigmoid curve to calculate EC50 would be considered absurd. Yet that is precisely how most labs treat time-course signaling data — collecting it, plotting it, and moving on without extracting a quantitative parameter. His ongoing research exists to close that gap. 3. GPCR Theory Was Built to Be Used One of Hoare's recurring arguments is that GPCRs are unusually tractable — not just as biological targets, but as analytical systems. The underlying pharmacological theory, from operational models of agonism to allosteric binding equations, was designed to be applied by bench scientists. The barrier is not the math itself but the habit of reaching for it. 4. A Mentor Who Worked at the Bench During a difficult stretch of his NIH postdoc, Hoare's supervisor Ted Usdin handed him a defined molecular biology project and spent two months working alongside him at the bench. The intervention was straightforward. The effect on Hoare's confidence — and ultimately his career — was not. He describes it as one of the moments his career most depended on. 5. The Variable Most Drug Programs Miss The CRF residence time story is not unique in Hoare's telling. Across multiple programs — including work on a vesicular transporter where in vitro affinity at pH 7.4 vanished entirely at the physiological vesicle pH of 5.5 — the pattern recurs: assays designed for convenience rather than physiological relevance produce data that can't predict what happens in vivo. The pharmacologist's job is to identify which variable is missing. 6. Emotional Intelligence as a Consultant's Core Skill Hoare was not expecting consulting to teach him about emotional intelligence. What he found was that clients arriving with a data problem are rarely arriving with just a data problem. The ability to serve as a sounding board — to help people relax around their data and see what was obscured by the pressure of having it not make sense — turned out to be as important as the pharmacological expertise he was hired for. 7. Early-Career Researchers Know More Than They Think Hoare makes an argument that surprised him when he first articulated it: a newly minted PhD who has spent six years on a single GPCR target knows things a company working on that receptor genuinely cannot find anywhere else. The practical knowledge of what buffer conditions work, what assay artifacts to expect, what the literature actually shows — that depth of expertise is marketable, and most early-career scientists don't recognize that they have it. Episode Timeline Timestamps are AI-generated from the transcript and may not reflect final edited video timing. 00:00 Sponsor message 00:35 Introducing Sam Hoare: pharmacology data analyst and GPCR consultant 03:19 Origin story — the ATP calculation that first connected math to biology 06:16 PhD with Philip Strange: allosteric modulation of dopamine receptors and the first aha moment 16:53 Why GPCRs? Tractability, accessible theory, and a famously generous field 22:55 NIH postdoc: Class B GPCRs, mentorship, and conversations with Nobel laureates 35:38 Into industry: the CRF receptor team at Neurocrin Biosciences 43:25 The off-rate aha moment: seven hours on the receptor versus fifteen minutes 52:22 Founding PharmaChanics: the decision to leave industry and go independent 01:16:46 Signaling kinetics: the time dimension most pharmacologists skip 01:45:04 Biased agonism and residence time as tools in the drug discovery toolbox 01:52:09 Building a consulting practice: network, marketing, and knowing your worth 02:05:22 Top three aha moments from a career in pharmacological data analysis Selected Quotes "The one that works had a really long residence time on the receptor. We measured it at room temperature and it didn't come off after seven hours. There was just no dissociation. And the one that didn't work in vivo came off in fifteen minutes." "Imagine doing pharmacology dose-response experiments for twenty years without applying the sigmoid curve fit to determine the EC50. To me, that's what we've been doing with time-course signaling data." "He basically gave me a cookie-cutter molecular biology project and worked with me at the bench directly for two months. It completely restored my confidence. I kind of owe a lot of my career to Ted." "My talent really is in data analysis. People would always come to me for that rather than for doing the experiments — and one of the reasons I set up my consultancy was that biology was becoming so technical that it was like I decided to specialize." About Dr. Samuel Hoare Sam completed his Ph.D. in biochemistry, studying allosteric modulation of dopamine receptors, from the University of Kent, United Kingdom. He then moved to the National Institute of Mental Health, researching pharmacological mechanisms of Class B GPCRs as part of his postdoctoral training. Today, Sam is a pharmacology data analyst and the founder of Pharmechanics LLC , a consultancy and data analysis company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics and the understanding of receptor systems. As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying in vitro pharmacology data to advance drug discovery. He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics, particularly GPCR antagonists. Before founding Pharmechanics in 2016, Dr. Hoare was a pharmacology leader in the pharmaceutical industry for 15 years at Neurocrine Biosciences . He guided the in vitro biology efforts of the company for numerous drug discovery campaigns. Sam is known for demystifying complicated and newly-emerging pharmacology concepts, enabling them to be applied by project teams in optimizing new molecules. I very much enjoyed chatting with Sam about his love for GPCRs, kinetics, and decorticate the complexities of GPCR function to better target receptors. Dr. Samuel Hoare on the web Pharmechanics LLC LinkedIn Pubmed Google Scholar YouTube Dr. GPCR Member ResearchGate Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Jean-Philippe Pin About Dr. Jean-Philippe Pin Jean-Philippe Pin participated in the discovery of metabotropic glutamate receptors. Since then, he has been studying the allosteric modulation and activation mechanism of this family of G protein-coupled receptors using innovative approaches, including biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic agents. His studies led to new concepts in the GPCR field, such as the activation of cell surface receptors by intracellular proteins; the regulation of GPCRs by both negative and positive allosteric modulators, and the asymmetric functioning of GPCR dimers. Dr. Jean-Philippe Pin on the web LinkedIn ResearchGate CNRS Fondation Bettencourt Schueller FRC Neurodon Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

A conversation with Dr. Silvio Gutkind on keeping a cancer research lab running at 10% occupancy, why rotation students act like a sorting hat, and why breakthroughs come from working hypotheses that fail. << Back to podcast list Strategic Partner(s) Silvio Gutkind: Building a Lab That Doesn't Shut Down Conversations that happen when a research community faces a shared constraint reveal as much about scientific practice as any experiment. Dr. Silvio Gutkind joins this resilience conversation from the UCSD Moores Cancer Center, where cancer patients cannot wait for normalcy to return. For Dr. Gutkind — carrying a personal loss in New York and leading a cancer center building that operated at 93% capacity during the early pandemic — the question was not abstract. He had to decide, week by week, what could pause and what couldn't, and whose careers would bear the cost of getting it wrong. He walks through the structure his team built: staggered schedules at 10–15% occupancy, written contracts with every lab member, a Zoom-based communication cadence, and an internal directive to read, think, plan, and write. The constraint did not slow the science; it redirected it. Bioinformatics projects flourished. Collaborations that would have waited for conferences started immediately. A harder question surfaces underneath: how much of what we call a lab is its physical walls, and how much is the community, the plan, and the willingness to let a failed hypothesis open a new direction? About the Guest Dr. Silvio Gutkind is Professor and Associate Director for Basic Science at the UCSD Moores Cancer Center. His research spans GPCR signaling in cancer biology, head and neck squamous cell carcinoma, and the molecular circuitry that drives tumor progression. Before moving to La Jolla, he spent decades at the NIH, where he led a branch at NIDCR. That dual lineage — extramural academic and intramural NIH — shapes how he thinks about research infrastructure, student training, and scientific community. Scientific Themes of the Conversation Institutional resilience and the architecture of a research lab under constraint The contract between scientific leadership and trainees during crisis Communication infrastructure as a substitute for physical proximity Chance and opportunity as drivers of a scientific career Rotation students as cross-pollinators between labs Why breakthroughs tend to come from working hypotheses that fail Key Insights from the Conversation Cancer centers don't get to pause. Dr. Gutkind describes operating his cancer research building at 93–94% capacity during the early pandemic because cancer patients couldn't wait for normalcy. The question was never whether to stay open — it was how to stay open safely, and how to absorb the stress that came with that responsibility. The NIH shutdown playbook made UCSD ready. Years at the NIH, where federal shutdowns were routine, gave Dr. Gutkind a pre-built mental model for what to freeze, what to protect, and what to let continue. When the pandemic hit, he reached for an infrastructure he already had. Every lab member needed a contract. Rather than making ad hoc decisions about who would come in and when, the team wrote down expectations — hours, distancing, critical versus deferrable work, and an explicit clause that no one should feel pressured to be on-site. The contract wasn't bureaucracy; it was protection, especially for students. The bioinformatics arm called it "heaven." Computational scientists suddenly had uninterrupted time at home with full data access and far fewer meetings. Dr. Gutkind reports that five years' worth of ideas accumulated in that stretch — more than the lab can realistically work through. "Physical distancing," not "social distancing." A small language correction with structural weight. Dr. Gutkind argues the scientific community grew closer during the pandemic, not further apart — the physical space contracted, but the community expanded through Zoom, shared drives, and unhurried collaboration conversations. Rotation students function like the sorting hat. Because trainees rotate through multiple labs, they carry science from one bench to another. Dr. Gutkind credits several of his most valuable collaborations to a rotation student recognizing a fit that no PI would have spotted from across campus. Breakthroughs come from working hypotheses that fail. Dr. Gutkind reflects that the most significant advances in his career didn't come from confirming a premise — they came from digging into why the premise broke. The discipline is not in being right, but in being willing to let go of the framework you built when the data refuses to fit it. Episode Timeline Timestamps were generated using AI for readability. 00:00 Welcome and introduction 01:46 Navigating research during the pandemic 03:30 Why cancer research couldn't stop 04:30 The NIH shutdown playbook 05:20 Writing the contract: occupancy, staggering, communication 06:50 The productivity paradox — "it's like heaven" 07:55 What will change after the pandemic 09:20 "Physical distancing, not social distancing" 11:31 Chance versus scientific knowledge in a career 12:20 Rotation students as the sorting hat 13:20 When the working hypothesis fails 14:30 Closing Selected Quotes "We have many more ideas than we can handle for at least the next five years." "I wouldn't call it social distancing — I would call physical distancing… as a community, we are even stronger." "These rotation students are like cross-pollination… almost like the sorting hat in Harry Potter." "Quite often, our breakthroughs are more often from when the working hypothesis did not work. The breakthrough came from getting deeper into why." About this episode Dr. J. Silvio Gutkind sheds light on his work and life since the beginning of COVID restrictions. A large component of his work is centered around dysregulated signaling in cancer and the development of novel mechanism-based cancer therapies. In this episode, Dr. J. Silvio Gutkind highlights how his past experience proves useful in current COVID times and potential benefits the changes in work environments can do for future collaborations. Dr. J. Silvio Gutkind on the web Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications More Publications from the Gutkind Lab on Pubmed Dr. J Silvio Gutkind on LinkedIn Gutkind Lab on Twitter UCSD Moores Cancer Center Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Get ready to connect, collaborate, and innovate at the Dr. GPCR Retreat — an immersive event uniting scientists, biotech leaders, and innovators in GPCR research. Dr. GPCR Retreat - Coming Soon - Please tell us your thoughts about scientific gatherings by filling out this short survey

Join the Dr. GPCR Affiliate Program and earn commissions by helping connect the global GPCR community. Share our ecosystem, courses, and events to advance drug discovery together. Dr. GPCR Affiliate Program Earn by Empowering the GPCR Ecosystem Help us connect scientists, founders, and innovators while earning commissions for every member, partner, or course you bring into the Dr. GPCR community. Become our Brand Ambassador Our vision is to build the best platform for the GPCR community and help you the scientists and business owners to share their experiences with others, get help, and find the perfect tools, colleagues, build their strategy and advance our field. As an ambassador, with the Affiliate Program, you'll earn a commission whenever your referral link is used and a qualified purchase has been made by your friends, colleagues, or followers who are also part of the GPCR field. Become our Brand Ambassador About Dr. GPCR Ecosystem We aspire to provide opportunities to connect, grow, and thrive together as a dynamic group. The goal is to better understand and exploit the druggability of GPCRs, together. The Dr. GPCR Ecosystem members have the opportunity to solve problems, find answers to their questions, identify the perfect service provider, and, most importantly, boost their GPCR project with just a few clicks. The Ecosystem is designed for all GPCR professionals to have an affordable and highly effective way to showcase their knowledge, connect, and advance the field, together. About the Dr. GPCR brand ambassador affiliate program Who can be a Dr. GPCR ambassador? Scientists and trainees with a strong GPCR background who like and want to create content by writing articles about their favorite GPCR topics and sharing these on social media platforms such as LinkedIn and other options listed at the end of this page. Who is eligible for the Dr. GPCR affiliate program? A GPCR background is mandatory independent of your current position and industry. You also must be an individual Dr. GPCR Ecosystem membership holder. For full details on eligibility, please read our Affiliate Policy . How do I apply for the affiliate program? To become an affiliate, you must create an account here . How does the Dr. GPCR affiliate program work? After becoming a member of the affiliate program, you'll get your personalized link where you can send your potential clients. After every qualified sale, you will earn a commission of $50. How does the commission work? Each qualifying sale earns a commission (excluding sale cancellations). Does it cost me anything to become an affiliate? The program is free to join; there are no monthly charges and no minimum sales requirements. However, the number of ambassador members is limited. Dr. GPCR reserves the right to remove the least active members from the program. Can I invite someone to participate? Yes! You can invite anyone to participate, and we welcome anyone if they are qualified. Do I need to sign a contract? There's no contract to sign when joining our program. You will be required to agree to our Terms and Conditions and our Affiliates Policy when you sign up on Ecosystem.DrGPCR.com. You can leave the program at any time by contacting us. Dr. GPCR may also remove affiliates from the program at any time. Is there an exclusivity agreement when joining? There's no exclusivity agreement. You can take part in other affiliate programs as well as be part of ours. Are affiliates outside of the U.S. eligible for the Affiliate Program? Yes, you may join the affiliate program as long as you have a verified PayPal account. What type of channels, tools, and techniques can I use to promote Dr. GPCR Ecosystem? OK to use: - Writing, blogging, guest blogging, - Podcast, video, vlog - Social media sharing, - YouTube & TikTok channels, - Business Page and website, - Informational and fan sharing, - Presentations and meetups. Not OK to use: Advertising Spam Anything misleading or annoying Social media bios Paying or offering intensives for the use of your link How do I track my earning? We use a third-party provider, GoAffPro.com , where you'll create your own account and through your dashboard, you can track all your activities. When will I receive my affiliate commissions? Affiliate payments are processed and sent directly to your PayPal in 7 to 30 days. We could hold payments up to 30 days to allow for processing, chargebacks, etc. Good Faith We introduce programs such as the Dr. GPCR Ambassador, in good faith and expect the same good faith in return. Please note that we may withhold awards where we believe customers are acting in bad faith or otherwise acting contrary to the intent of this program. To be clear, commercializing, advertising, publishing, mass distributing, selling, or paying for the use of referral links is not appropriate, and we will not honor such links. We cannot cover every nefarious scenario, nor will we attempt to, but we do promise to be fair and reasonable. Closure We are so excited about the Dr. GPCR Ambassador program. It will be a remarkable journey and fun to build together the "next-generation" platform for the B2B industry. With your help, we can create a world where the living experience is joyful and worry-free. Are you ready? Sign up , explore, and connect with us. Become our Brand Ambassador

Discover our transparent and fair affiliate policy, supporting Dr. GPCR Ecosystem. Join us to make a positive impact while earning commissions. << Back Affiliate Policy Dr. GPCR Ambassador Program Dr. GPCR, Corp., (“Dr. GPCR”) provides its Service to you through our websites referred to as Dr. GPCR, Ecosystem.DrGPCR.com , DrGPCR.com . Dr. GPCR Affiliate Program ( DrGPCR.com , Ecosystem.DrGPCR.com ) offers eligible affiliates, including blogs and other third-party websites (“Affiliates”), the opportunity to earn commissions on qualifying sales that originate from links to the Ecosystem.DrGPCR.com website on an Affiliate’s site. This Affiliates Policy explains your rights and responsibilities when participating in the Dr. GPCR Affiliates Program. This policy is a part of our Terms of Use . By participating in the Dr. GPCR Affiliates Program, you agree to this policy and all legal documents. 1. Eligibility and Enrollment in Dr. GPCR Affiliates Program Prospective eligible affiliates must apply and be approved by Dr. GPCR to gain access to the Affiliate Program. The Affiliate program is only available to individual members who have paid their yearly membership fees in full. Group membership holders are excluded from the Affiliate Program. Prospective eligible affiliates are evaluated based on criteria such as type of site, site quality, site content, variety of site content, social media content, and, most importantly, scientific knowledge. During the application process, prospective eligible affiliates may be asked to provide additional information to support any listed criteria. The following types of websites are prohibited from participating in the Affiliates Program: “Cash-back” or voucher sites (websites that offer rewards for buying goods through referral links); Price comparison sites; Sites using “pop-ups” or “pop-unders” (websites that launch “pop-up” or hidden windows on users’ browsers); Sites that violate the Dr. GPCR Trademark Policy ; Sites that exist solely to promote Dr. GPCR & Dr. GPCR Ecosystem; Sites with content related to sexual, religious, political, or other sensitive matters. Prospective eligible affiliates must apply, and approved affiliates must enroll directly through Ecosystem.DrGPCR.com . Signing up to the program via a sub-network is not permitted. Affiliates may leave the Affiliate Program and terminate this agreement at any time by sending an email to Hello@DrGPCR.com . Dr. GPCR reserves the right to remove Affiliates from the Affiliate Program and refuse service to anyone, for any reason, at any time. Participation in the Affiliate Program may be limited to affiliates located in certain countries and is void where prohibited by law. Dr. GPCR reserves the right to approve or reject any application to join the Affiliate Program for any reason. Depending on where an affiliate is located, they may be subject to varying regulations regarding endorsements and testimonials. For example, in the United States, the Federal Trade Commission outlines specific requirements regarding disclosure. The affiliate's responsibility is to be aware of and comply with any applicable regulations that pertain to their site. Dr. GPCR cannot provide legal advice; we urge you to consult a legal expert if you believe these or other regulations may apply to you. 2. Commission Rates, Qualifying Sales, and Payment As an affiliate, you can receive commissions for qualifying sales. Commission rates are determined on a case-by-case basis and may vary based on various factors such as the type of site and content. Commissions may increase during limited-time special promotions. The current commission rate is: $100 (January 2022) Qualifying sales are sales made on the Ecosystem.DrGPCR.com or DrGPCR.com websites by users who arrived on the Dr.GPCR sites by clicking an approved link on an Affiliate’s site (an “Affiliate Link”). Affiliate links will be sent to you after approval, including URLs, banners, or other creative assets. The affiliate may not alter any text links or creative assets made available through the Affiliates Program platform to receive payment. Affiliates are also requested not to hardcode Affiliate Links into their sites. The Affiliate Program uses unique links to verify qualifying sales. Commissions are paid on qualifying sales made through the affiliate's unique links. This means that an Affiliate can receive a commission for a qualifying sale if the deal was created. Commissions are not paid on sales that are canceled. Commissions are subject to review and other limitations for fraudulent activity. Dr. GPCR reserves the right to withhold commissions if fraudulent activity is found. Dr. GPCR pays affiliates via a PayPal account, provided to us when a member joins. If the PayPal email address changes, it is the affiliate's responsibility to notify the Affiliate Program of the changes to ensure proper commission payments. The affiliate is responsible for the entire amount of PayPal's processing fees when payments are made. Dr. GPCR will be solely responsible for processing every order placed by a customer via affiliate links. Affiliates are not authorized to collect payments or sell Dr. GPCR membership or products from other websites as a “reseller,” and no “resale” rights are granted in ANY way. Affiliates are not authorized to sell any of these products on auction sites. Affiliates are not permitted to give away copies of any of these products. Dr. GPCR will also be solely responsible for all customer service inquiries. All affiliates understand and acknowledge that no physical products will be shipped. 3. Program Restrictions Affiliates that violate any of the following program restrictions may be suspended or removed from the Dr. GPCR websites and may not receive any commissions. Paid Search Dr. GPCR maintains a strict policy on paid search activity. Affiliates must comply with the following conditions on any ad platform, including, but not limited to, search engines, content networks, and social networking sites: Affiliates are not permitted to bid or appear on searches that include the term “Dr. GPCR”, "DrGPCR", "Doctor GPCR", "Ecosystem Dr. GPCR", "EcosystemDrGPCR". Dr. GPCR Ecosystem", DrGPCREcosystem";- Affiliates are not permitted to bid or appear on extended or hybrid searches that include the terms “Dr. GPCR”, "DrGPCR", "Doctor GPCR", "Ecosystem Dr. GPCR", "EcosystemDrGPCR". Dr. GPCR Ecosystem", DrGPCREcosystem"; Affiliates are not permitted to bid or appear on misspellings or variations of searches that include the terms “Dr. GPCR”, "DrGPCR", "Doctor GPCR", "Ecosystem Dr. GPCR", "EcosystemDrGPCR". Dr. GPCR Ecosystem", DrGPCREcosystem"; Affiliates are not permitted to use Dr. GPCR trademarks in any paid search activity, including ad text, ad copy, or display URLs; Affiliates are not permitted to direct link PPC activity to the Dr. GPCR sites; this includes using the DrGPCR.com or Ecosystem.DrGPCR.com website as a display URL; Affiliates are not permitted to send traffic through automatic redirects on a website page;- Affiliates are not permitted to use the Dr. GPCR name (including misspells and variations) as a sub-domain or sub-folder. Responsibility for Your Site You are solely responsible for your website, including its development, operation, maintenance, and all materials that appear on or within it. Dr. GPCR disclaims all liability for your site, social media, and other content, and any of your users’ claims relating to your site, and you agree to defend, indemnify, and hold Dr. GPCR harmless from and against all claims relating to your site. 4. Modification Dr. GPCR may modify any of the terms and conditions within the Affiliate Agreement at any time, at its sole discretion. These modifications may include, but are not limited to, changes in the scope of available referral fees, fee schedules, payment procedures, and Affiliate Program rules. If any modifications are UNACCEPTABLE TO YOU, your only recourse is to terminate this Agreement. If you CONTINUE PARTICIPATION IN THE PROGRAM following the changes in the new agreement, it will be considered your acceptance of the change. Are you ready? Sign up, explore, and get in touch with us. Become our Brand Ambassador Please read carefully our Legal Policies and Disclaimers to understand how Dr. GPCR conducts business Affiliate Policy Content and Conduct Policy Content Guidance Privacy Policy Terms and Conditions Trademark Policy

<< Back to podcast list Strategic Partner(s) Dr. Nyla Naim, Dr. Michael Lemieux & Dr. Jason Nasse About Dr. Nyla Naim Nyla is a Senior Scientist on the Scientific Support Team at Addgene . She received her Ph.D. at the University of Pittsburgh and continued her postdoctoral research at the University of Vermont studying cellular signaling, biosensors, and optogenetics. Nyla supports biomedical research by connecting researchers with resources and promoting reproducible science. Dr. Nyla Naim on the web LinkedIn Dr. GPCR Ecosystem About Dr. Michael Lemieux ''My name is Michael (Mike) Lemieux and I am a Connecticut native. I completed my Ph.D. in molecular and cell biology at UConn and then joined Addgene as a Quality Control Scientist in 2015. Since then I transitioned into a Scientific Support role to leverage my passion for helping people! Beyond my interest in science, I am a strong advocate for graduate education reform and I love to write.'' Dr. Michael Lemieux on the web Addgene Blog Dr. GPCR Ecosystem About Dr. Jason Nasse Dr. Jason Nasse is a senior scientist at Addgene specializing in the use of AAV viral vectors. He obtained his Ph.D. in Neuroscience from Ohio State University focusing on synaptic plasticity and adrenergic receptor modulation of both pre-and postsynaptic properties. By taking a very non-traditional path to obtain a Ph.D. Dr. Nasse has had the opportunity to experience how science is performed across different sectors and around the country. Prior to his role at Addgene, Jason held roles in academia, big pharma, and non-profit research organizations. Dr. Jason Nasse on the web LinkedIn Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Five scientists audit what AI can and can't do for GPCR drug discovery — from orphan receptors and biased signaling to the true-negatives problem nobody writes into grant proposals. Recorded at the 3rd EARNEST meeting. << Back to podcast list Strategic Partner(s) EARNEST Panel: Can AI Accelerate GPCR Drug Discovery? In October 2020, five scientists gathered virtually at the 3rd EARNEST meeting to debate a question that has only grown more urgent: can artificial intelligence actually accelerate GPCR drug discovery, or is it mostly a rebranding of methods the field has used for decades? Panelists from InterAx Biotech, Rockefeller University, and the University of New Mexico — computational chemists, systems biologists, structural biologists, and drug-discovery veterans — drew on their combined experience to separate what machine learning can credibly do for GPCR research from what still depends on pharmacological judgment. The conversation moves from definitional clarity (AI is not machine learning, and neither is simple computational modeling) to the practical realities of building usable datasets, deorphanizing receptors, handling generative models, and confronting the true-negatives problem that quietly breaks so many published models. For any scientist whose grant proposal now contains the phrase "machine learning" whether they fully believe in it or not, this panel is an honest audit of what the technology can deliver today and where it still falls short. About the Panelists Dr. Maria Waldhoer is Chief Scientific Officer at InterAx Biotech in Switzerland. A pharmacologist by training, she spent more than six years in early R&D at Novo Nordisk before turning to systems biology approaches for connecting in vitro signaling data to in vivo drug behavior. Dr. Aurélien Rizk is Chief Technology Officer at InterAx Biotech. Trained as a mathematician and computer scientist, his doctoral work focused on developing new methods for modeling GPCR signaling pathways. Dr. Yaroslav Nikolaev is a scientist at InterAx Biotech with a dual background in biology and computation. His research combines biomolecular NMR, structural biology, and machine learning to study how GPCRs function dynamically. Dr. Thomas Sakmar has run a laboratory at Rockefeller University for roughly thirty years. His group contributed to the early cloning of GPCRs in the mid-1980s and has since pushed the boundaries of GPCR biochemistry — including early homology modeling, coarse-grained molecular dynamics, and genetic code expansion for site-specific chemistry on receptors. Dr. Tudor Oprea is Principal Investigator at the University of New Mexico and coordinator of the Illuminating the Druggable Genome Knowledge Management Center. An MD-PhD who has practiced machine learning since 1989, he built Pharos, the public-facing data platform for the IDG program, and co-developed G1, the first agonist for GPR30, which reached an IND for melanoma. Scientific Themes of the Conversation The definitional boundary between AI, machine learning, and computational modeling Data quality as the rate-limiting step for machine learning in GPCR pharmacology Orphan receptor deorphanization and the limits of learning from known peptides Generative models, scoring functions, and the role of molecular dynamics in ligand design The true-negatives problem and how it distorts biological models The hybrid future: chemical intuition, experimental judgment, and where computation still falls short Key Insights from the Conversation AI and machine learning are not the same thing, and the difference matters. Machine learning finds patterns in defined datasets; AI aims to substitute for human reasoning more broadly. Using the terms interchangeably blurs what each approach can realistically deliver in a pharmacology workflow. The barrier isn't messy data — it's missing metadata. Most pharmacology datasets aren't useless for ML; they're incomplete. Buffers, incubation temperatures, time points, co-expression conditions, the specific Emax reference — these are the details that determine whether a dataset can be pooled with others or must stand alone. Deorphanization via AI is possible, but constrained by what we already know. Random-forest classifiers trained on known peptide ligands can find new orphan-receptor pairings. But the remaining orphans may be orphans precisely because they don't resemble anything we've characterized — which caps what this class of model can find. The bottleneck in structure-guided ML isn't the algorithm. The panel agreed that the real limits are the availability of high-resolution GPCR structures and the computational cost of molecular dynamics simulations needed to capture the dynamic conformations behind signaling. True negatives quietly wreck biological models. Most published models rely on inferred negatives — genes or molecules assumed inactive by convenience. When one panelist replaced inferred negatives in an autophagy model with CRISPR-validated true negatives, the model's predictions changed radically. Chemical intuition has no AI equivalent yet — and won't soon. The experience of a seasoned medicinal chemist mentally docking a molecule from a 2D structure is not a skill current models replicate. The panel expects a hybrid future, not a replacement one, for the next five to ten years. Olfactory GPCRs remain a trillion-dollar opportunity the field has largely ignored. GPCR-targeting drugs represent roughly 0.9 trillion dollars in global sales across 75 countries. Olfactory GPCRs — which account for a large fraction of the receptor class — have been systematically sidestepped for lack of tractable in vitro screening methods. Episode Timeline 00:00 Welcome from Yamina Berchiche 01:36 Panelist introductions 11:41 AI vs machine learning — the definitions that matter 15:21 The undrugged majority: 400 non-olfactory GPCRs, only 160 drugged 20:12 What makes a pharmacology dataset usable for machine learning 24:41 Advice for small academic labs entering the field 30:34 Can AI help deorphanize understudied receptors? 37:01 Reading GPCR signaling dynamics with computational models 39:53 Generative models, scoring functions, and molecular dynamics 50:32 The true-negatives problem and the limits of inferred datasets 52:30 Hype vs reality in AI drug discovery 55:05 Where the GPCR field goes in the next five years Timestamps were generated using AI for readability. Selected Quotes "My computational team told me, 'this receptor is not using arrestin to internalize. There has to be an arrestin-independent thing there.' And I'm like, that's rubbish. Never picked it up. Complete rubbish. And then a year later or so, I get a call from a colleague who said, 'oh, we've tested this compound as a negative control because we thought it doesn't need arrestin to internalize. And now we put it in this CRISPR knockout cell and — it does.'" — Dr. Maria Waldhoer "In 1989, as a med student in Romania, I used BASIC to model the variation in heart rate and blood pressure for 11 patients. I wrote an 11 polynomial that fit everything, so I thought I had solved the problem with drug discovery. I have learned a lot since." — Dr. Tudor Oprea "Dan Rich worked on HIV protease inhibitors. He would look at the 2D structure and basically mentally do a docking and tell you whether that's a good protease inhibitor or not. I think there are people who have worked in the GPCR field that can do a similar exercise." — Dr. Tudor Oprea "If you only make big enough numbers, big enough networks, big enough algorithms, suddenly intelligence pops out on the other side. [Roger Penrose] said, well, it's simply because they cannot think of anything else to do yet." — Dr. Maria Waldhoer About this episode Listen to this fantastic round table discussion that I had the privilege to moderate with Alexander Hauser . Our guests were Maria Waldhoer , Tudor I. Oprea , Thomas Sakmar , Aurelien Rizk & Yaroslav Nikolaev . The explosion of biomedical data such as in genomics, structural biology, and pharmacology can provide new opportunities to improve our understanding of human physiology and disease. In recent years, machine learning (ML) and artificial intelligence (AI) methods have received a significant boost in attention. ML/AI can be powerful for identifying abstract patterns within large data where traditional methods would be oblivious to. This comes without the need for manual feature engineering as systems can learn through implicit rules from the data provided. G protein-coupled receptors (GPCRs) mediate a vast variety of critical biological processes and provide an ideal case study for quantitative, and multi‐scale integration of these amounts of data to gain novel insights into receptor biology. How can we best leverage these exciting new techniques in areas such as protein structure prediction, bioactive ligand discovery, in-vivo translation ability, or in our understanding of signaling determinants? Here, we would like to discuss the opportunities, weaknesses, and advantages of these new technologies, which may contribute to probe our favorite targets at all scales. For more information on the ERNEST network, visit https://ernest-gpcr.eu/ . Dr. Yamina Berchiche on the web Website LinkedIn Publications Twitter Facebook Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Stephen Ferguson The History of the Great Lakes GPCR Retreat with Dr. Stephen Ferguson About Dr. Stephen Ferguson Dr. Stephen Ferguson is a Professor in the Department of Cellular and Molecular Medicine at the University of Ottawa. He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994). He did his postdoctoral training with Dr. Marc G. Caron at Duke University (1994-1997), where he and his colleagues investigated the role of G protein-coupled receptor kinases and beta-arrestin in regulating G protein-coupled receptor endocytosis, trafficking, and signaling. He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of Canada MacDonald Scholar (1998-2003) and Heart and Stroke Foundation of Ontario Career Investigator (2003-2016). He was a recipient of Canada's Top 40 under 40 award in 2004 and received Queen Elizabeth II, Diamond Jubilee Medal, in 2012. He has also received both Junior (2001) and Senior (2005) investigator awards from the Pharmacological Society of Canada. Most recently, in 2021, he was elected as a Fellow of the Canadian Academy of Health Science (FCAHS). His research career has focused on the investigation of the regulation of G protein-coupled receptors signaling mechanisms in health and disease. He currently holds multiple research grants from the Canadian Institutes of Health Research (CIHR) for his research investigating the role of metabotropic glutamate receptor signaling in Huntington’s and Alzheimer’s disease. Dr. Stephen Ferguson on the web Carlton University Canada Research Chairs Twitter ResearchGate LinkedIn Dr. GPCR Ecosystem Great Lakes GPCR Retreat on the web 21st Great Lakes GPCR Retreat More about previous GPCR Retreat meetings Dr. GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) The Scientist's Compass: From Academia to Entrepreneurship with Dr. Dmitry Veprintsev In this episode, Yamina sits down with Prof. Dmitry Veprintsev , a molecular pharmacologist at the University of Nottingham, to discuss his scientific journey, GPCR research, and the intersection of academia and entrepreneurship. Key Takeaways: From Protein Folding to GPCRs – How Dmitry transitioned from biophysics and protein folding to cannabinoid receptor research, guided by key mentors like Michel Bouvier. Why GPCRs? – The challenge and excitement of working with notoriously difficult-to-study membrane proteins. The Power of Asking the Right Question – Dmitry emphasizes that mastering a technique isn’t enough—true scientific breakthroughs come from formulating the right biological questions. Building Z7 Biotech – The unexpected journey into biotech entrepreneurship, providing GPCR profiling services to pharma and biotech companies. Interdisciplinary Research & Future Directions – Exploring combinatorial drug actions, receptor interactions, and novel profiling approaches. Networking & Career Growth – Overcoming introversion, the importance of talking to people, and how networking (or just genuine curiosity) opens doors in science. 💡 Big Takeaway? Whether in academia or industry, success comes from curiosity, persistence, and knowing your values. Tune in to hear how Dmitry navigated his career, the challenges of studying GPCRs, and why talking to others will always lead to answers! Summary made with AI About Dmitry Veprintsev Dmitry is Professor of Molecular and Cellular Pharmacology at the Centre of Membrane Proteins and Receptors (COMPARE), University of Nottingham, where he provides leadership in structural and biophysical pharmacology of G protein coupled receptors. He is author of over 100 papers, including several in Nature, Science and Cell. Dmitry studied biophysics at the Moscow State University, followed by a PhD (1998) in protein folding at the Russian Academy of Sciences and at the Ohio State University, USA. He joined the MRC Centre for Protein Engineering and later at the MRC Laboratory of Molecular Biology in Cambridge, UK as a postdoctoral fellow and later as a staff scientist, focusing on the biophysical studies of the tumour suppressor p53. In 2010 he became a group leader at the Paul Scherrer Institute and ETH Zürich in Switzerland, changing his attention to structural pharmacology of G protein-coupled receptors (GPCRs). In 2017 Dmitry became a full professor at the Centre of Membrane Proteins and Receptors, COMPARE, a joined venture between the University of Birmingham and the University of Nottingham. In 2021 he co-founded Z7 Biotech, developing and providing innovative GPCR drug screening and precision pharmacology services. Dmitry Veprintsev on the web LinkedIn Veprintsev Lab Z7 Biotech University of Nottingham Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Access expert CRO advisory services through the Dr. GPCR Ecosystem. Get guidance, strategies, and insights to optimize your GPCR research and drug discovery projects. Home About Services News Get in Touch Welcome CRO & Vendor Advisory Your Science Is Strong. Your Process Should Be, Too. I help CRO teams bring structure to collaboration—so your data gets acted on, not overlooked. When biotech partners trust your process, they come back again and again. You deliver high-quality data. But when timelines shift, expectations blur, or feedback loops break down, even the best work can lose momentum. Let’s turn your scientific rigor into results that move programs—and people—forward. Power My Discovery Biotech Clients Want Results - Not Confusion Every CRO I work with has great science—but clients still struggle to understand the value. Here's what I hear from biotech teams: “We’re not sure what we’re getting—or when we’re getting it.” “The science is solid, but the communication is scattered.” “The data looks fine, but it doesn’t help us make decisions.” Great science isn’t enough if clients don’t feel aligned, informed, and in control. That’s where I come in. How I Help CROs Deliver High-Impact Science That Biotech Teams Trust Biotech Clients Stay in Sync With Your Team I work to strengthen communication & collaboration: • Facilitate smoother communication between technical teams and biotech clients • Set clear expectations and deliverables to build trust and reduce delays • Align teams across roles—from assay execution to client updates Data Turns Into Decisions—Not Delays I help turn great science into clear deliverables • Define program objectives and guide assay plans that support partner decisions • Translate discovery data into clear, actionable formats biotech teams can use • Streamline deliverables to reduce review cycles and accelerate go/no-go calls & shorten timelines Your Science Stays Focused on What Matters We work together to position your CRO for growth • Refine your offering to match what biotech teams actually need • Position your services to shorten sales cycles and increase repeat business • Turn client feedback into improvements that boost trust and outcomes Here's What CROs Are Saying "Before working with Yamina, we were generating high-quality data across biotech programs but often navigating evolving expectations and goals from different stakeholders. After partnering with her, communication became clearer, deliverables were better defined, and collaboration across teams ran more smoothly. She helped streamline complex projects and made the CRO–client relationship more effective and productive." - Anne Marie Quinn, CEO Montana Molecular Frequently Asked Questions 01 What kinds of CROs do you work with? Any CRO focused on GPCRs, pharmacology, discovery biology, or antibody discovery—regardless of size or location. 02 What happens when I reach out? We'll start with a focused conversation about your programs and current challenges. You'll leave with clarity—even if we don't end up working together. 03 Can you help on an ongoing basis? Yes. I offer both short-term consulting and ongoing partnerships depending on your needs. Power My Discovery Send me a message First name* Last name Company name* Email* How Can I Help?* Send Message or Book My Call Menu Home Services About Ready to collaborate? Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution across biotech, VC, and CRO teams. Get in touch Connect LinkedIn Podcast Dr. GPCR Calendly ©2023-2025 All rights reserved by FindYooour, LLC & Dr. GPCR Corp Proudly created with Wix.com

Dr. Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights. << Back to podcast list Strategic Partner(s) Leadership, Impact, and GPCR Signaling with Dr. Michelle Halls In this episode Dr. Michelle Halls shares how dissecting the spatial organization of GPCR signaling opens new doors in drug discovery. From early discoveries in cyclic AMP signaling to uncovering ultrasensitive receptor responses at femtomolar ligand concentrations, her work highlights why receptor localization and protein complex assembly matter for therapeutic targeting. This conversation is especially valuable for scientists developing functional assays, fluorescence-based tools, and high-throughput GPCR screens. Inside This Episode How ultrasensitive GPCR signaling emerges from pre-assembled receptor–effector complexes at the plasma membrane. Why receptor localization and scaffolding dramatically shift functional readouts in disease models. What early cyclic AMP assays revealed about spatial signaling long before high-content technologies existed. The moment when femtomolar ligand concentrations uncovered unexpected receptor sensitivity. How an integrated training and lab structure at Monash Institute of Pharmaceutical Sciences fosters innovation in functional assay development and GPCR research. Why It Might Hit Home If you’ve ever: Faced unexpected assay behavior at ultra-low ligand concentrations, Balanced innovation with robust validation under real experimental constraints, Tried to map signaling heterogeneity in disease-relevant models, Built assays that need to work in real biology—not just on paper, …this episode will resonate. About the Guest Michelle Halls is an Associate Professor at Monash University and Deputy Theme Leader of Drug Discovery Biology at Monash Institute of Pharmaceutical Sciences. She leads the Spatial Organisation of Signalling Laboratory, where her team investigates how GPCRs orchestrate localized signaling events, how these mechanisms are hijacked in disease, and how they can be leveraged for therapeutic innovation. Michelle earned her PhD in Molecular Pharmacology at Monash University, then trained in single-cell biology as an NHMRC CJ Martin Fellow at University of Cambridge. She established her lab in 2011, and today she is a Viertel Senior Medical Research Fellow. Her recognitions include the 2024 ASCEPT Achievement Award, the 2023 BPS Geoffrey Burnstock Prize, and the 2019 Faculty Future Research Leader Award. More about Michelle Halls Monash Institute of Pharmaceutical Sciences Bluesky LinkedIn Articles about this Podcast Episode How GPCR Spatial Signaling Sparked a Scientific Journey From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Collaboration Built an Innovation Engine 🎓 Want more like this? Get behind-the-scenes conversations, advanced assay development strategies, and practical GPCR tools inside Dr. GPCR Premium . Join a global GPCR community of scientists and biotech leaders. 👉 Join now Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Shivani Sachdev About Dr. Shivani Sachdev "Dr. Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health. Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors relevant for treating osteoporosis, diabetes, and pain. She received her undergraduate degree in Biotechnology from KIIT University in India. She subsequently joined Professor Mark Connor's laboratory at Macquarie University in Australia. Dr. Sachdev pursued Ph.D. in the same lab where she investigated the molecular pharmacology of cannabinoid receptors. She is also very active within the pharmacology community and currently serves on the editorial board of the British Journal of Pharmacology. Given her expertise in GPCR pharmacology and scientific communication, she is poised to make valuable contributions to the field and expand our understanding of GPCR signaling." Dr. Shivani Sachdev on the web NIDDK ReseachGate Google Scholar LinkedIn Twitter Dr. GPCR Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>